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ABSTRACT 
 
 
The purpose of this study was to assess the impact of virologic monitoring frequencies on  
treatment failure, adherence to therapy, and the emergence of drug resistance in HIV-1  
infected patients. A quantitative, meta-analysis was conducted to investigate the virologic  
outcomes of infrequent and frequent Viral Load (VL) testing among patient on combination  
antiretroviral therapy (cART). Data was collected through a self-designed data collection  
form. Two comparison groups emerged being guided by the VL monitoring frequency. In  
group I, the health outcomes were compared for (≥3 VLs per year) versus (≤2 VLs per year)  
and (2 VLs per year) versus (≤1 VLs per year) for group II. Data were analysed using the  
Cochrane's statistical software, RevMan v5.3. The findings support (2 VLs per year) as the  
optimal VL monitoring strategy for stable and virologically suppressed patients and there is  
nothing to be gained by (≥3 VLs per year). 
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
1.1 INTRODUCTION 
Botswana has continued to expand treatment access while maintaining excellent treatment 
outcomes for HIV with a view that keeping first line treatment failure rates at a minimum will 
reduce the overall long-term cost in managing patients. This will be achieved through the 
interventions focusing on improving adherence as well as early detection and management of 
antiretroviral (ARV) treatment failure (Botswana Ministry of health 2012:96). Viral load (VL) 
monitoring remains the gold standard for determining adherence, and antiretroviral therapy 
(ART) effectiveness. Frequent monitoring enables early and accurate diagnosis of treatment 
failure before the development of drug resistance mutations, thereby improving the quality of 
care that HIV patients receive (Roberts et al 2012:1). 
According to Kent, McGrath, Loannidis and Bennish (2003:2), the optimal frequency of VL 
monitoring has not been rigorously determined in randomized trials; and since 2003 some 
data from randomized trials suggest that virological outcomes may be further improved with 
even more frequent monitoring. Testing every 3 months rather than every 6 months was 
associated  with  modest  increases  in  health  outcomes (Bendavid,  Young,  Katzenstei, 
Bayoumi, Sanders & Owens 2008:5). The need to have frequent determination of viral load as 
currently  practiced  in  resource  rich  countries  has  been  challenged (Paintsil 2011:6) 
considering the data reviewed in resource limited settings, indicating little gains in measuring 
viral load more frequently than every 6-12 months. 
A study conducted by Romih, Zidovec, Gedike, Lukas and Begovac (2010:5) in Croatia, a  
middle income country,  , examined patients with less VL testing compared to those with more  
frequent VL testing . The researchers found contradicting outcomes, and actually suggested  
that patients with more frequent VL testing were more likely to have virologic failure than  
patients with less frequent VL testing Romih et al (2010:6). Importantly, it was observed that in a  
population  of  patients  who  were  initially  virologically  well  suppressed  and  considered  
adherent, there is little if anything to be gained in measuring viral load more frequently than  
every 6-12 months. According to Romih et al (2010:7) treatment failure was not preceded by  
less frequent VL tests, and suggests that considerable savings can be achieved by less 
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frequent monitoring of stable patients without compromising the efficacy of the treatment 
intervention. A question that remains unanswered is whether it is necessary to have frequent 
viral load determination. 
 
1.2 BACKGROUND TO THE RESEARCH PROBLEM 
Botswana, a middle-income country with a per capita GDP of $17,700 in 2015 (World  
Factbook 2016) still needs to design appropriate testing intervals. Optimal VL monitoring  
should lead to more timely detection of treatment failure, more effective, targeted adherence  
counselling and prevent treatment failure. Estill, Egger, Johnson, Gsponer and Wandeler  
(2013:1) in their study sought to assess the cost-effectiveness of switching to second-line ART  
with different monitoring strategies. Additionally, Tucker, Bien and Easterbrook (2013:2),  
examined optimal monitoring strategies for HIV-infected individuals for outcomes such as,  
drug resistance, switch rates to second-line ART and adherence. However, these researchers  
excluded studies that examined only different frequencies of monitoring or thresholds for  
switching to second-line ART. 
 
In Botswana, the emergence of resistant strains of HIV might have little to do with the lack of  
health care infrastructure but rather the lack of social support needed for patients to adhere to  
demanding regimens. Romih et al (2010:1) explain that in well-resourced settings clinical  
guidelines recommend that viral-load testing be done every 3 months, hence leading to more  
adherence interventions or early changes in therapy that will reduce the risk of accumulation  
of resistance mutations. 
 
A study from Khayelitsha, Cape Town found that a first VL at three months rather than six  
months with targeted adherence interventions for patients with high VL may improve long-term  
virologic suppression and reduce switches to costly second-line ART (Kerschberger, Boulle,  
Kranzer, Hilderbrand & Schomaker 2015:1). Rafiee, Kariminia and Wright (2014:1) have also  
highlighted that annual viral monitoring could lead to substantial increase in the numbers of  
failing  patients  who  develop  resistance  and  potentially  increasing  transmission  of  drug  
resistance virus. However, Schneidera, Puthanakit and Kerr (2011:1) argues that less frequent  
viral load monitoring is likely to provide substantial clinical benefit to HIV-infected patients on  
ART, and suggest that after a single screening at 6 months, the optimal frequency of  viral  
load monitoring should be annual. In a study conducted by Estill, Aubriere & Egger (2012:2)  
using VL monitoring to assess treatment adherence and/or virologic failure, they indicate that 
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VL monitoring does not allow detection of non-adherence in real time. 
 
A meta-analysis on these studies will overcome the lack of power and generalizability by 
combining the findings from studies conducted in varying populations. Intuitively, it is 
reasonable that the requirement for laboratory monitoring of stable patients might be less 
frequent, yet there is conflicting data to support this notion. Recognizing the lack of 
consensus on this subject, the researcher conducted a meta-analysis to investigate the 
virologic outcomes of infrequent VL testing among clinically and immunologically stable 
cART-treated patients. Current practice may be based on expert opinions; however, medical 
decisions should be evidence-based, hence this meta-analysis is likely to be an efficient 
method of accessing reliable and relevant evidence. 
 
1.3 STATEMENT OF THE RESEARCH PROBLEM 
Botswana has the opportunity to finally gain epidemiologic control of HIV. The year 2016 has  
marked  an  important  turning point  in the  Botswana  National HIV  Response  with  the  
implementation of the New HIV ‘Treat All’ Strategy (Botswana Ministry of health 2016: 3).  
According to Estill et al (2012:2), ‘Test and treat’, which involves large-scale testing for HIV  
infection and immediate ART, is a subject of debate. In particular, it may be difficult to  
achieve the necessary high levels of adherence to therapy. Maintaining and monitoring  
proper adherence to therapy is an increasingly important priority for ART programmes.  
Kerschberger, et al (2015:1) indicate that, early virologic failure is mainly due to poor  
adherence  and  treatment  interruptions  rather  than  virologic  resistance.  According  to  
Kerschberger et al (2015:5) early detection of suboptimal adherence accompanied by  
targeted adherence interventions may lead to better virologic outcomes. Determining optimal  
viral  load  monitoring  frequency  to  detect  early  adherence  problems  is  essential  to  
maximising the durability of first-line regimens. 
Botswana first started the ART Programme in 2002, and it is now poised to become one of  
the few countries in the world to achieve the UNAIDS 90-90-90 targets. By 2016, Botswana  
had come close to virtually eliminating Mother-to-Child transmission and had rolled-out ART  
services to all hospitals and over 600 clinics (Botswana Ministry of health 2016: 3).To  
maintain this success achieved  by up-scaling the coverage of ART, a renewed national  
consensus on the optimal frequency of viral load monitoring is needed. Currently, the WHO  
guidelines recommend viral load testing every six months (WHO 2014:76). The Botswana 
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Ministry of health  (2016:32) recommends laboratory monitoring schedule at 6 months 
following a 12 months test after initiating ART. The debate over the long-term benefit of 
various monitoring frequencies still stands. Every monitoring frequency carries different 
impact on detection of sub-optimal adherence, long-term virologic suppression and rates of 
switches to costly second-line ART (Keebler, Revill & Braithwaite 2013:1). 
 
This meta-analysis study seeks to find and summarize evidence on the health outcomes of 
different virological monitoring frequencies and provide further insights into the acceptability 
and feasibility of universal testing and treatment in Botswana. Factors associated with the 
frequency of VL have as yet not been evaluated. 
 
1.4 PURPOSE OF THE STUDY 
According  to  Babbie  (2007:87-90,  the  purpose  of  the  study  should  explain  the  final 
conclusions that the research study hopes to reach. The purpose of this study was to evaluate 
the impact of virologic monitoring frequencies on virologic treatment failure, adherence to 
therapy, and the emergence of drug resistance in patients infected with HIV. The study 
attempted to determine the optimal frequency of VL measurement to optimize patient 
outcomes and maximize cost-effectiveness. 
 
1.4.1 Objectives of the study 
In systematic reviews, questions are stated broadly as review ‘Objectives’, the specific 
accomplishments the researcher hopes to achieve by conducting the study (Polit & Beck 
2012:93). To guide the study focus, the objectives included ways to obtain answers to 
research questions. 
 
The objectives for this study were to 
•   determine the optimal frequency for determining HIV RNA levels 
•   investigate whether HIV-1 infected patients on a stable and fully suppressive first line  
 regimen could safely be monitored less frequently than the current recommendations  
 of every 3 months. 
•   evaluate whether frequent viral load monitoring would improve patient adherence and  
 thereby contribute to improved virological outcomes. 
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1.5 RESEARCH QUESTIONS 
A research question is an answerable inquiry into a specific concern or issue. It is essential to 
a good research design and is the fundamental core of a study. The nature of the 
research question shapes the research, determines the methodology, and guides all stages of 
inquiry, analysis, and reporting (Polit & Beck 2012:55-58). This study sought to answer the 
following research questions: 
 
•   What is the optimal frequency of VL monitoring? 
•   What are the health benefits of frequent monitoring (≥3 VLs per year) versus less  
 frequent monitoring (2 VLs per year)? 
•   What is the difference in the risk of virologic failure between the frequent monitoring  
 (≥3 VLs per year) and the less frequent monitoring (2 VLs per year)? 
•   What effect does frequency of monitoring has on patient adherence to therapy? 
 
1.6 SIGNIFICANCE OF THE STUDY 
In the context of implementing the New HIV ‘Treat All’ Strategy (Botswana Ministry of health  
2016:3), which involves large-scale testing for HIV infection and immediate ART, the  
emergence of HIV drug resistance (DR) is unavoidable.  As the number of patients  
accessing these treatments increases, so will the number of patients who fail them. Less  
frequently monitored patients are likely to face increased risk of treatment failure, hampering  
the benefits of the ‘Test and treat’ strategy. To maintain the success achieved by up-scaling  
the coverage of ART in Botswana, monitoring frequency of VL testing is based on expert  
opinion and the recent World Health Organization recommendations. However, medical  
decisions should be evidence-based. 
 
In  Botswana,  determination  of  plasma  VL  is  considered  an  essential  component  for  
monitoring effectiveness of CART and it is performed routinely to confirm virological failure in  
patients.  However,  as  resources  rarely  permit,  the 2013  WHO  guidelines  overlay  
considerable debate about the benefits and frequency of routine viral load testing.  When  
allocating resources, the benefits of any proposed VL testing frequency must balance the  
risk of virologic failure with the benefits of decreased cost of monitoring. This study  
investigated whether patients on a stable and fully suppressed regimen could safely be seen  
less frequently without significant increase in the risk of treatment failure. The financial cost  
of laboratory diagnostics represents a substantial portion of total health care costs for HIV- 
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infected persons. Therefore, less frequent VL monitoring could result in significant reductions  
in financial costs of laboratory diagnostics, provided that such monitoring strategy is proven  
to be sufficient and safe. The best interval for routine HIV monitoring has been identified as  
area in which gaps in knowledge exist. This study could contribute to the body of knowledge  
to better understand optimal virologic monitoring frequencies for HIV-1 infected individuals. 
 
1.7 DEFINITION OF CONCEPTS 
Concepts may refer to theoretical creations that are based on observations which cannot be  
observed directly or indirectly (Babbie 2007:43). Babbie (2007:44) further defines concepts  
as "basic building blocks of theory", that are abstract elements representing classes of  
phenomena within the field of study. In Alston (2003:39), concepts are terms which usually  
summarises clusters of related elements. According to Babbie (2007:110), the process of  
classifying and specifying perceptions or experiences by use of particular terms in research  
is called conceptualization. Conceptualization is the process of coming to an agreement  
about what the terms mean, and then produce a specific, agreed-on meaning on a concept  
for purposes of a particular research. Polit and Beck (2012:30) summarises the definition of  
concepts as constructs derived by mutual agreement from mental representation of some  
phenomenon (conceptions). 
 
For the purposes of this study, it was necessary to specify exact meanings for all concepts.  
The following concepts related to this study were identified and described to clarify in  
advance what they mean in order to draw meaningful conclusions about them and indicate  
how variables were observed and measured (Babbie 2007:110; Polit & Beck 2012:30). 
1.7.1 Adherence 
Adherence refers to the willingness and ability of patients to follow health-related advice, take 
medication as prescribed, attend scheduled appointments, and complete recommended 
investigations (Moosa & Jeenah 2012:144). In this study, adherence means the ability of the 
patient to take medication as prescribed and then self-report using a validated adherence tool. 
The adherence was measured either as a score or a rate, which is the number of doses taken, 
divided by the number prescribed. 
1.7.2 Anti-retroviral (ARV) drugs 
Anti-retroviral (ARV) drugs are drugs that reduce the level of HIV in the patient. Classified 
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according to their  mechanism of action, different groups of ARVs in use include Fusion 
Inhibitors,  Non-Nucleoside  Reverse  Transcriptase  Inhibitors(NNRTI),  Nucleoside  and 
Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease-Inhibitors (PI) (EPH 2008, sv 
“Antiretroviral Medications”). 
1.7.3 Evaluation 
An evaluation typically reviews and investigates how well a specific program, practice, or  
intervention is working. Generally, the term evaluation research is used when researchers  
are trying to determine the effectiveness of a rather complex program, rather than when they  
are testing a specific entity. Moreover, evaluations often try to answer broader questions  
than simply whether an intervention is more effective clinically than care as usual. There are  
various types of evaluations. Cost-benefit analyses are typically done in connection with  
impact and outcome analyses (Polit & Beck 2012:192-193, 410). Evaluation in this study  
refers to an investigation on the virologic and treatment outcomes when viral load is  
measured frequently compared less frequent monitoring, among HIV-infected patients on a  
stable regimen. This is to determine the impact of changing monitoring from frequent to less  
frequent monitoring, and to determine the most efficient and  effective monitoring strategy. 
1.7.4 First-line treatment 
First-line treatment is the primary treatment regimen or regimens that are generally accepted  
by the medical establishment for initial treatment. In Botswana, it is common practice to use  
a combination of Truvada and Dolutegravir for new and previously initiated adults, pregnant  
women, and adolescents (>40kg) (Botswana Ministry of health 2016:16). These are either  
Protease inhibitors (PI) or Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)-based  
HAART fist-line regimen. 
1.7.5 Frequency of monitoring 
Frequency of monitoring refers to viral load measurements aimed at detecting changes in  
the health status of populations (eg, every 3, 6, 12, or 24 months) after initiating ART (A  
Dictionary  of  Epidemiology 2008, “monitoring”).  In  this  study  frequent  monitoring  is  
considered to be ≥3 VLs per year and the less frequent monitoring is 2 VLs per year. 
1.7.6 Human Immunodeficiency Virus (HIV) 
Human Immunodeficiency Virus (HIV) is a retrovirus that primarily infects vital components of 
the human immune system and is the virus that causes AIDS (EPH 2008, sv “AIDS”). 
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1.7.7 HIV-1 Infected Patients 
According to ENR 2006, Sv “Population Genetics and Human Health”, infection with the 
human immunodeficiency virus type 1 (HIV-1) is associated with progressive and profound 
loss of immune function that places infected patients at risk for opportunistic infections, 
malignancies, and death. 
 
1.7.8 Meta-Analysis 
Meta-analysis is a technique for integrating quantitative research findings statistically, where  
the findings from a study are treated as one piece of datum. The findings from multiple  
individual studies (similar with respect to population, outcome and intervention) focused on a  
specific research question are then combined to create a data set that can be analysed in a  
manner similar to that obtained from individual studies. Thus, instead of study participants  
being the unit of analysis, individual studies are the unit of analysis in a meta-analysis. The  
essence of a meta-analysis is the calculation of a common metric; an effect size with a  
confidence interval for every study. The effect size represents the magnitude of the impact of  
an intervention on an outcome, or the degree of association between variables (Polit & Beck  
2012:120). 
1.7.9 Treatment failure 
Treatment failure is defined as a persistent virological failure (Botswana Ministry of health  
2016:20). In this study treatment failure is considered to be two successive VLs of >200  
copies/ml. 
 
1.7.10 Responses to Antiretroviral Therapy 
Responses to Antiretroviral Therapy (ART) is explained as health outcomes susceptible to 
direct measurement which reflects the state of health of persons, like treatment failure of 
first-line HIV regimens demonstrated by virologic failure (A Dictionary of Epidemiology 2008, 
“health indicator”). In this study, the response to antiretroviral therapy could either be viral 
suppression or treatment failure. The secondary outcomes include the time for the detection of 
virologic failure and the person-years spent with virological failure. 
 
1.7.11 Viral Load (VL) 
Viral Load (VL) is a measure of the level of the virus in HIV infected patients. It is measured  
at six months post initiation of ART and six monthly thereafter (Botswana Ministry of health  
2016:32). 
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1.7.12 Virologic failure (VF) 
Virologic failure is described as viral load >400 copies/ml 6 months after ART initiation or viral 
load rebound to > 400 copies/ml after documented full suppression. In Botswana, 
documented virologic suppression to <400 copies/mL as confirmed by two priority viral loads 
tests (Botswana Ministry of health 2016:20). 
 
1.7.13 Virologic Monitoring Frequencies 
This is the rate of intermittent testing and analysis of measurements aimed at detecting 
changes in the quantity of viral load copies/ml. The frequency is the number of occurrences of 
a repeating Virological test (detecting the presence of viral nucleic acid) per unit time. A 
frequent VL testing would be (≥3 VLs per year) and a less frequent schedule would be (≤2 VLs 
per year) (Bendavid et al 2008:1). In this study, two comparison groups emerged being guided 
by the virologic monitoring frequencies: 
•   Group 1: Frequent monitoring (≥3 VLs per year) versus less frequent monitoring (≤2  
 VLs per year) 
•   Group 2: Frequent monitoring (2 VLs per year) versus less frequent monitoring (≤1  
 VLs per year) 
 
1.8 FOUNDATIONS OF THE STUDY 
Polit and Beck (2012:132) indicate that the theoretical foundation of the study is seen as the  
rationale to enhance the utility of a study. The authors further mention that it is difficult to see  
how a theory would enhance the value of the findings of a research that has a utilitarian goal  
(Polit & Beck 2012:133). This study focused on the right and wrong of health outcomes  
(consequences)  of  choosing  one  VL  monitoring  frequency  over  other  VL  monitoring  
frequencies.  The  study  was  designed  to  determine  the  optimal  viral  load  monitoring  
frequency to detect early adherence problems as an attempt to maximise the durability of  
first-line regimens. 
 
Viroligic failure is a critical health outcome and taken as a variable because it varies with  
specific conditions. The study sought to understand the system of variables that cause this  
particular health outcome to be occurring when one VL monitoring frequency is chosen over  
another. The studies of interest were treated as the "carriers" of the variables. Variables, in  
turn have attributes (categories or values). Babbie (2007:10-11) describes attributes as  
characteristics or qualities that describe an object. Variables are logical groupings of 
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attributes. Treatment failure as a health outcome can be categorized as virologic failure,  
immunologic failure, clinical failure, or some combination of the three. Almost all antiretroviral  
(ARV) management decisions for treatment failure are based on addressing virologic failure  
(indicated by plasma viral load limits). Virologic treatment failure may be due to drug  
resistance which may also develop if a person cannot tolerate a drug or has poor adherence.  
Furthermore, Babbie (2007:14) indicates that sometimes attributes can be thought of as  
categories that make up a variable. Thus for example, ≥3 VLs per year and ≤2 VLs per year  
are attributes and monitoring frequency is the variable composed of the two attributes. 
1.9 INTRODUCTION TO RESEARCH DESIGN AND  
 METHODOLOGY 
Scientific inquiry is dedicated to making observations and interpreting what is observed. A  
study design is a plan that determines what to observe and analayse, why and how (Babbie  
2007:84). According to Polit and Beck (2012:144) study design is the overall plan for  
addressing a research question, including specifications for enhancing the study’s integrity.  
Methodology  is  the  technique  used  to  structure  a  study  and  to  gather  and  analyze  
information in a systematic fashion in order to achieve an intended goal (Polit & Beck  
2012:422). 
 
A quantitative approach was followed. Quantitative research adopts the positivist paradigm of 
research. This traditional paradigm underlying the scientific approach was appropriate for this 
study as it assumes that there is a fixed, orderly reality that can be objectively studied and 
proven (Polit & Beck 2012:419). In this study, a correlation between the variables was 
examined to compare the health outcomes (dependent variable) of patients when virlogic 
monitoring frequency varies (independent variable) 
A descriptive systematic review and meta-analysis was conducted. A number of studies of  
the same intervention have since been published (Bendavid et al 2008:5; Kerschberger et al  
2015:10; Romih et al 2010:1; Schneidera et al 2011:1;Rafiee et al 2014:1). A systematic  
review and meta-analysis was required to determine consistency among these studies. This  
settled controversies arising from these apparently conflicting studies. The degree of data  
inconsistencies was formally assessed, and reasons for different results were explored and  
quantified. According to Nieswiadomy (2012:76) meta-analysis statistically combines the  
results of several studies that have examined the same topic. In this study, several research 
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studies were simultaneously examined using statistical measures. The results of different 
studies were combined and statistically analysed. 
 
1.9.1 Study setting and population 
According to Polit and Beck (2012:27, 423), a study setting is the specific place where data  
collection occurs. It ranges from naturalistic (field) settings to formal laboratories and  
conditions in which data collection takes place in a study. The published articles relating to  
this study were located using the Medline system, supplemented by the use of other indices  
such as UNISA online libraries, the Cochrane Library, CINHAL, EMBASE and World Health  
Organization (WHOLIS) library database, Web of Science, PsycINFO, PubMed and Google  
Scholar.  Specific  investigators  active  in  the  area  of  interest  were  consulted  to  find  
unpublished studies. Peers and Experts were consulted in an attempt to identify all relevant  
studies. A population is all the individuals or objects with common, defining characteristics  
indicating what attributes the participants or subjects should possess, and thereby clarifying  
the group to which the study results can be generalized (Polit & Beck 2012:46). The  
population for this study was all published articles focusing on HIV Viral Load Monitoring  
Frequency on HIV-1 patients. The target population for this study was studies identified from  
January 2006 to August 2016; with no geographic restrictions. 
1.9.2 Sample and Sampling Methods 
According to Babbie (2007:184), a sample is a subset of a larger population from whom 
information is gathered, and sampling is the process of drawing a fair representative portion 
from the population. A purposive or judgmental sampling method was used on the basis of the 
knowledge of the population, its elements, and purpose of the study. 
Relevant studies were identified with search terms including “viral load monitoring”, “drug  
resistance”, “treatment adherence”, and “virologic failure”. The sample of selected studies  
included only those which examined the frequency of VL testing and the association with  
health outcomes (treatment failure, adherence, drug resistance). Potentially relevant titles  
were identified through database searching and other sources. Studies meeting eligibility for  
inclusion were subjected to meta-analysis. The inclusion criteria are described in detail in  
chapter 3. 
1.9.3 Data collection 
The concepts in which researchers was interested were measured, observed, and recorded. 
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Data collection dealt with the observational aspect of the study and the process of obtaining  
the sample and collecting data for the study (Babbie 2007:37; Polit & Beck 2012:48). This  
study, being a Meta-analysis involved and relied on existing available data gathered in  
previous studies. 
A standardised data collection form was used in the extraction process. Data were extracted  
on the following: study name; authors; antiretroviral combinations used; year of publication  
or presentation; study design categorised according to whether cohort, part of a clinical trial,  
or  patients  were  randomised  to  particular  treatment;  participant  characteristics (age);  
definition of virological failure; and numbers of virological failures with viral load greater than  
400 copies per ml. Furthermore, resistance data for virological failures were extracted.  
There was no form of human intervention (treatment or medical related procedures) involved  
in this study. According to Kimberlin and Winetrstein (2008:3) the three basic approaches to  
validity are content validity, construct validity, and criterion-related validity. The most valid  
instrument has both external validity and content validity. External validity is the extent to  
which the results of a study can be generalized from a sample to a population. Content  
validity  refers  to  the  appropriateness  of  the  content  of  an  instrument (Kimberlin  and  
Winetrstein 2008:4). The validity and reliability of the instrument was achieved through a pre- 
test  of  the  instrument,  focus  of  the  questions  on  the  content  of  the  subject  under  
investigation, review of the tool by the supervisor. More information on reliability and validly  
of the data collection tool is presented in chapter 3. There were no copyright issues as the  
instrument was self-designed. More details on data collection and ethical considerations are  
discussed in chapter 3. 
1.9.4 Data analysis 
Polit and Beck (2012:278) indicate that data collected in a study do not by themselves 
answer research questions or test hypotheses. Data were systematically analyzed to detect 
patterns. Data analysis was devoted to the organization and analysis of research data. 
According to Babbie (2007:37), data analysis looks for meaningful patterns observed among 
variables and where appropriate, compares what is logically expected with what is actually 
observed. Techniques for combining indicators into composite measures of variables, i.e 
Indexes and scales were developed by Quantitative data analysts (Babbie 2007:180). 
Quantitative data analysis could be a univariate analysis, which involves one variable, or 
bivariate analysis which involves two variables or multivariate analysis, the simultaneous 
examination of several variables (Babbie 2007:432). 
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Collected and coded data were uploaded to analytical computer software Excel for statistical  
analysis. For each comparison of monitoring frequencies, the study reported the estimated  
relative risks (RR) and the 95% confidence interval (CI) for all key outcomes for each of the  
studies. Random effects model were used to generate a summary effect size, should it be  
appropriate to pool research findings that compare the same monitoring strategies and  
report  comparable  health  outcomes.  The  outcomes  to  be  examined  included  drug  
resistance, switch rates to second-line ART and treatment adherence. Estimates of group  
means (and SEs) of baseline variables (age, log10 viral load) was calculated using inverse  
variance weights. Studies were stratified for analysis into those with intensive monitoring  
(more frequently than 3 months), and those with infrequent (less frequently than every 3  
weeks).  After  studies  are  stratified  into  two  groups  by  viral-load  monitoring  intensity  
(infrequent vs frequent), health outcomes were compared. Reliability of data is explained in  
chapter 4. 
 
1.10 STRUCTURE OF THE DISSERTATION 
 
The structure of the dissertation is as follows: 
Chapter 1: Overview of the study 
Chapter 2: Literature review 
Chapter 3:  Research design and methods 
Chapter 4: Analysis, presentation, and description of the research findings 
Chapter 5:  Conclusion and recommendations 
 
1.11 CONCLUSION 
This chapter highlighted an overview of this study with special emphasis on the background 
and problem statement, and the purpose of the study. The objectives and significance of the 
study were outlined and the research methodology was introduced. The next chapter, 
chapter 2, presents the literature review. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
A literature review typically summarizes results of past studies, suggests potential reasons for 
inconsistencies in past research findings, and directs future investigations. Traditional 
narrative reviews identify articles relevant to the topic of interest, examines the results of each  
article  to  see  whether  the  hypothesis  was  supported,  and  provides  an  overall 
conclusion. Recently, systematic research syntheses that include meta-analyses have taken 
the place of purely narrative reviews of empirical literature to address many limitations of the 
narrative review by using statistical procedures to combine the results of previous studies 
(Alasuutari, Bickman & Brannen 2008:536). 
 
This chapter briefly deliberates on the monitoring frequency in viral load monitoring, and its 
outcomes. Several studies have investigated whether HIV-infected patients on a stable and 
fully  suppressive  combination  antiretroviral  therapy (cART)  regimen  could  safely  be 
monitored less often than the current recommendations of every 3 months (Bryant, Smith & 
Keiser 2013:1; Caniglia, Sabin, Robins, Logan, Cain &  Hernán 2016:1; Haubrich, Currier, 
Forthal, Beall, Kemper, Johnson, Dube, Hwang, Leedom, Tilles & McCutchan 2001:1; 
Reekie,  Mocroft,  Sambatakou,  Machala,  Chiesi,  Lunzen,  Clumeck,  Kirk,  Gazzard  & 
Lundgren 2008:1; Romih et al 2010:1; Schneider et al 2011:1; Weissman, Singh, Dykema & 
Parker 2016:1; Young, Hart, Buchacz, Scott, Palella & Brooks 2015:1). 
 
2.2 MONITORING FREQUENCY 
According to Weissman (2016:1), people infected with HIV require life-long care. Therefore,  
it is important to consider more effective treatments and determine an updated monitoring  
frequency. The aim of routine frequent VL testing in patients with undetectable VL is to  
detect virological failure early, leading to adherence interventions or early changes in  
therapy that will limit ongoing viral replications and reduce the risk of accumulation of  
resistance  mutations (Romih  et  al. 2010:7).  Current  guidelines  for  HIV  management  
recommend monitoring plasma HIV-1 RNA level every 3-6 months in patients on a stable 
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antiretroviral regimen (Chaiwarith, Praparattanapan, Nuntachit, Kotarathitithum, Sirisanthana & 
Supparatpinyo 2011:1). 
 
 
A randomized clinical trial by Weissman (2016:5) explored the optimal frequency of HIV  
monitoring needed in stable patients with HIV and on ART, and the findings suggest that  
less frequent monitoring may be considered for adherent patients who have VL suppression  
of 2 years with VLs conducted every 6 months. Caniglia et al (2016:1) reports that  
monitoring frequency of virologically suppressed individuals can be decreased from every 3  
months to every 6, 9, or 12 months. According to Young et al (2015:7), biannual VL  
monitoring for the qualifying patients could greatly save costs without jeopardizing patient  
safety. This could help allocate the saved resources to expand and improve other areas of  
HIV care and management. 
The cost-effectiveness and cost-utility of different frequencies of monitoring plasma viral load  
among  HIV  positive  children  initiating  ART  in  a  resource-limited  setting  has  been  
investigated (Schneider et al 2011:6) and the optimal frequency of VL monitoring was found  
to be annual, after a single screening at 6 months. Therefore, infrequent VL monitoring is  
likely to provide substantial clinical and financial benefit. However, this is in disagreement  
with the findings in Haubrich et al (2001:6) who report that frequent VL monitoring of every 2  
months results in better treatment management, and significant improvements in HIV virus  
load  suppression,  compared  with  infrequent  monitoring  of  twice  yearly.  The  clinical  
consequences of delaying ART switching and allowing ongoing virological failure are likely to  
be  serious.  Reekie et  al (2008:7)  says  that  patients  who  have  spent  less  time  with  
uncontrolled viraemia while on cART were less likely to experience treatment failure. 
 
2.3 VIROLOGIC FAILURE 
Weissman et al (2016:3) defines virological failure as two successive VLs of >200 copies/ml,  
and confirms that among virally suppressed persons with HIV, there are no differences in  
virologic failure after 24 months on ART. Young et al. (2015:1) sought to assess whether  
viral load (VL) monitoring frequency was associated with differential rates of virologic failure 
(VF) among HIV Outpatient Study (HOPS) participants and did not detect statistically  
significant difference in frequency of VF among patients undergoing frequent versus less  
frequent  VL  testing  even  after  multivariable  adjustment.  Therefore,  having  infrequent  
monitoring may not be associated with an increased rate of VF as compared with frequent 
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monitoring. Furthermore, Chaiwarith et al. (2011:1) found no difference in virologic failure  
after 24 months, among HIV-infected patients who had VL monitoring every 4 months versus  
every 6 months. Additionally, reducing the monitoring frequency is likely to detect virologic  
failure almost as frequently as using standard 6-month monitoring (Bryant et al 2013:3). 
However, these findings conflict with the data found in Caniglia et al (2016:5), a study that  
compared VL monitoring strategies with respect to virologic outcomes, focusing on the HIV- 
CAUSAL  Collaboration,  which  includes  prospective  cohort  studies  from 6  European  
countries and the United States. Caniglia et al (2016:5) finds that monitoring every 9-12  
months increases the risk of virologic failure compared with monitoring every 3 months.  
Haubrich et al (2001:2) reports that more frequent VL monitoring results in a reduction in  
virus load nearly twice than seen with less frequent virus load monitoring. Therefore, a  
statistical  strategy  for  assembling  the  results  of  these  separately  conducted  studies,  
sometimes with conflicting findings would be necessary to decide on the optimal VL  
frequency. 
 
2.4 ADHERENCE 
Visits for monitoring purposes are often used as opportunities to reinforce the need for  
treatment adherence and decreased monitoring may affect adherence rates. According to  
Reekie et al (2008:8) it is possible that less frequent monitoring will result in poorer  
adherence, in turn leading to a higher risk of treatment failure. The findings for virologic  
failure  in  Caniglia  et  al (2016:7)  might  reflect  intermittent  or  poor  adherence  among  
individuals monitored less frequently. It is reasonable to think that more frequent VL would  
improve  patient  adherence  and  thereby  contribute  to  improved  virological  outcomes.  
However, in a randomized clinical trial conducted by Weissman et al (2016:2), there was a  
difference in adherence scores with regards to VL monitoring frequency. This data is similar  
to data reported in Haubrich et al (2001:6); another randomized study that evaluated  
whether more frequent VL monitoring might motivate patients to improve adherence to their  
therapy, and the trial found that the frequent group did not have better adherence than the  
infrequent group. 
 
2.5 DRUG RESISTANCE 
According to Reekie et al (2008:8), infrequent VL makes patients to spend longer with  
detectable viraemia before it is identified, thus increasing the risk of developing resistance. 
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Haubrich et al (2001:7) indicates that better outcomes observed in the frequent group may  
have been due to earlier detection of loss of virological control and to more rapid treatment  
adjustments that prevented the development of antiretroviral resistance. Less frequent  
monitoring of patients on ART may be associated with resistant mutations. However, in  
Weissman et al. (2016:4) there are no statistically significant differences between the less  
frequent and frequent monitoring groups on development of new resistant mutations. In  
another study, the median time of exposure to replicate virus was found to be 147 days,  
which is well below the median time for the development of Thymidine Analog Mutations  
(TAMs) in clinical trials of 594 days (Bryant et al 2013:3). Therefore, infrequent monitoring  
may not increase the risk of developing resistant virus, particularly TAMs. 
 
2.6 CONCLUSION 
Literature has shown that HIV-infected persons who have access to medical care and are 
prescribed combination antiretroviral therapy (cART) are increasingly living longer and 
experience  lower  rates  of  treatment  failure (Young  et  al 2015:1).  The  studies  were 
conducted in specific type of populations and this affects generalizability. The next chapter 
presents the research design and methodology. 
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CHAPTER 3 
 
RESEARCH DESIGN AND METHODOLOGY 
 
3.1 INTRODUCTION 
According  to  Polit  and  Beck  (2012:24),  research  methods  refers  to  the  techniques  
researchers use to structure a study and to gather and analyze information relevant to the  
research question(s). Rigorous methodological procedures aim to eliminate or minimize  
bias, or to detect its presence to take into account in interpreting the data and enhance the  
quality of the study findings (Polit & Beck 2012:12, 35). This chapter explains how this  
study was planned, structured and executed. The subjects’ inclusion and exclusion criteria,  
search strategy for studies, data collection, and measures to evaluate the risk of bias of  
included studies are discussed. 
 
This study’s purpose was to evaluate the effects of frequency of virologic monitoring on 
virologic failure, adherence to therapy, and drug resistance as a response to ART therapy in 
patients infected with HIV-1. This was achieved by evaluating studies that were deemed 
eligible for this research. 
 
3.2 ELIGIBILITY CRITERIA 
Eligibility criteria are the specific characteristics that delimit the study population. This 
covered   substantive   methodologic   factors   and   stipulated   the   specific   variables   or 
phenomena to be studied (Polit & Beck 2012:204, 386). This study focused on randomized 
trials. However, it included other studies regardless of quality and incorporated information 
about quality into the analysis; such as observational studies with comparators, cohort 
studies, controlled clinical trials and case-control studies. Therefore the inclusion and 
exclusion characteristics of the studies were considered as follows: 
3.2.1 Inclusion criteria 
Inclusion criteria are a set of predefined characteristics used to identify subjects to include in  
a research study (ERD 1964, sv “Inclusion criteria”). The inclusion criteria were as follows:  
Studies 
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• pertaining to Viral load monitoring of antiretroviral therapy, 
• on resistance to antiretroviral drugs used to treat HIV and AIDS. 
• which evaluated virologic monitoring frequency and primary health outcomes 
•  that examined virologic failure, drug resistance, switch rates to second-line ART and 
adherence. 
•  that evaluated the frequency of viral load monitoring after initiation of ART and its 
effects on virologic and treatment outcomes. 
•  that examined different frequencies of monitoring or thresholds for switching to 
second-line ART, optimal frequency of monitoring. 
• must have primary comparisons of the frequency of viral load monitoring strategy. 
• of comparisons of particular interest on virologic monitoring. 
•  should have treatment outcomes such as treatment failure, adherence, and drug 
resistance measurements related to the effects of monitoring frequency. 
•  are observational studies (cohort and case-control) which included comparators. 
•  with populations that include ARV-naive, ARV-experienced or a combination of these 
without restriction on age, ethnicity, race, and nationality. 
•  with specific population of HIV-1 infected patients that were initially virologically well 
suppressed, on ART that must include either a NNRTI or PI as part of their treatment  
regimen. 
•  only in English language. 
 
3.2.2 Study exclusion criteria 
Exclusion criteria specify the characteristics that ruled out certain subjects not to be included in 
the study because they did not possess or meet the inclusion criteria (Polit & Beck 
2012:274).The exclusion criteria were as follows: 
•   Letter, editorial, non-systematic review, observational studies without comparators,  
 case report, cross-sectional study design. 
•   Studies evaluating ART in patients who have failed more than one regimen. 
•   Studies evaluating substituting ART due  to toxicities rather than switching ART due  
 to clinical, immunologic, or virologic failure. 
 
3.3 SEARCH FOR STUDIES 
The search was on original articles with online accessible full text available in database and 
pre-selected online data base. 
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3.3.1 Electronic Searches 
Using search terms appropriate for each database, the researcher used the HIV and AIDS  
Cochrane   Collaborative   Review   Group   search   strategy   to   design   a   structured,  
comprehensive and exhaustive search strategy in an attempt to identify all relevant studies  
regardless of publication status. The researcher performed a computer-assisted search in  
MEDLINE, EMBASE, and Cumulative Index of Nursing and Allied Health (CINAHL) via  
EBSCO from 2006 to 3 July 2017. The researcher identified grey literature through the  
Science Citation Index from 2006 to 3 July 2017. In addition, the researcher searched the  
UNISA online libraries, the Cochrane Library, and World Health Organization (WHOLIS)  
library database. The searches were performed without limits to setting or age; but were  
limited to studies published in English language from 2006 to 3 July 2017. Keywords used  
for database searching included the following; virological monitoring, virologic treatment  
failure,  adherence  and  therapy,  viral  load  testing,  HIV-1  drug  resistance,  first-line  
antiretroviral therapy and adherence treatment failure, switch and monitoring. 
3.3.2 Searching other resources 
The researcher screened reference lists of all included studies identified by the above 
methods to identify potential and eligible studies missed by electronic searches. Additional 
studies were searched using the 'Related Articles' feature through PubMed. The researcher 
aimed to access theses and dissertation abstracts from institutions known to be involved in 
research regarding virologic responses to antiretroviral therapy in HIV-1 infected patients. The 
researcher also contacted researchers involved in studies with possibly relevant but 
unpublished data to locate relevant data. 
 
3.4 SELECTION OF STUDIES 
The literature search was conducted with the assistance of the UNISA Information Search  
Librarians. The researcher screened all titles and abstracts of identified studies from  
searches of electronic databases to determine whether they met the inclusion criteria. This  
initial screen removed all titles which did not fit the inclusion criteria. For each potentially  
eligible study identified by the electronic search or by other methods, the full-text version  
was obtained for further assessment. Each study was evaluated for inclusion or exclusion  
using a study eligibility screening form based on pre-specified inclusion criteria (Annexure 
B). 
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3.4.1 Types of interventions 
This study looked for studies with primary comparisons of the frequency of viral load 
monitoring strategy. Comparisons of particular interest were infrequent monitoring (≤2 VLs 
per year) versus more frequent virologic monitoring (≥3 VLs per year), and the role of 
adherence monitoring in these comparisons. 
 
3.4.2 Types of outcome measures 
This study included studies that assess the optimal virologic monitoring frequency and its 
effects on virologic outcomes. Treatment failure, adherence, drug resistance measurements 
related to the effects of monitoring frequency were included as outcomes. 
 
3.5 DATA EXTRACTION AND MANAGEMENT 
Data were extracted from the selected studies using a standardized data-extraction sheets in 
“pen-and-pencil” forms (or the electronic equivalent) (Annexure C), and the meta-analysis was 
performed. The type of tool used for data extraction was a paper and pencil modified into an 
electronic version (word document). All relevant data were transferred to other electronic 
platforms like the Cochrane's statistical software, RevMan v5.3, for computer- 
assisted statistical analyses. Data extracted included: 
 
•   Study details such as citation, study design, type, start and end dates, country and  
 location of study (e.g. higher income vs. lower income country). 
•   Assessment of methodological quality 
•   Possible sources for heterogeneity 
•   Participant details which included study population eligibility (inclusion and exclusion)  
 criteria, ages, population size, and attrition rate, relevant baseline characteristics  
 (e.g. treatment naive or experienced). 
•   Interventions details, e.g. frequency of Virologic monitoring 
•   Outcome details, e.g. HIV-RNA viral load measurements and proposed levels for  
 suppression as defined by the authors, adherence, and resistance. 
 
3.5.1 Advantages and disadvantages of an electronic version (word  
 document) of Paper and pencil method 
In a study by Elamin, Flynn, Bassler, Briel, Alonso-Coello and Karanicolas (2009:1) some 
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data-extraction tools for conducting systematic reviews were assessed. They provided  
guidance about choice of data extraction tools such as paper and pencil, spreadsheets, web- 
based surveys, electronic databases, and web-based specialized software. Each tool offers  
benefits and drawbacks (Elamin et al 2009:3). The advantages of the paper and pencil were  
as follows: 
 
 
•  “Pen-and-pencil” forms (or the electronic equivalent) carried a relatively low cost of 
implementation  and  use  (no  need  for  computer  programming  or  specialist 
software). 
•   The method was suited for this small local project (few primary studies included,  
 with only one reviewer). 
•   It was easy to set up or contextualise the data extraction form to be most  
 compatible with the research to facilitate data management. 
•   No training was required and less time was needed for the researcher to get  
 familiar with the tool and use it efficiently to input data. 
•   The electronic versions could be shared with the supervisor of this study through an  
 e-mail (portability and accessibility). 
•   The method was useful during pre-test of data extraction items and procedures. 
 
On the other hand, the disadvantage of paper and pencil was that it took a lot of time to 
transfer data to the electronic platform for computer-assisted statistical analyses. 
 
3.6 ASSESSING RISK OF BIAS IN INCLUDED STUDIES 
Kimberlin and Winetrstein (2008:6, 7) indicate that a bias is a systematic error in results or 
inferences, which can lead to underestimation or overestimation of the true intervention 
effect. It was important to assess the risk of bias in all the studies in the review irrespective of 
the anticipated variability in either the results or the validity of the included studies. This 
appraisal process was the assessment of risk of bias in the included studies. 
The researcher assessed the methodological quality of each study being guided by the  
Cochrane Collaboration domain-based evaluation tool which contains items that are directly  
related  to  internal  validity.  The  relevant  domains  in  the ‘risk  of  bias  assessment’  a  
component of Annexure C were sequence generation, allocation concealment, blinding,  
incomplete outcome data, selective outcome reporting, and other potential biases. The 
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domains were evaluated for assessment of the selection bias, performance bias, detection 
bias, attrition bias, and reporting bias as explained as follows: 
•   Selection bias: for systematic differences between baseline characteristics of the  
 groups that are compared. 
•   Performance bias: for systematic differences between groups in the care that was  
 provided, or in exposure to factors other than the interventions of interest. 
•   Detection bias: for systematic differences between groups in how outcomes were  
 determined. 
•   Attrition bias: for systematic differences between groups in withdrawals from a study  
 causing incomplete outcome data. 
•   Reporting bias: for systematic differences between reported and unreported findings.  
The researcher assessed each of the above domains as low risk of bias (low), high risk of  
bias (high), or uncertain risk of bias with correspondent judgment criteria (see Annexure C). 
3.7 ETHICAL CONSIDERATIONS RELATED TO DATA  
 COLLECTION 
According to Polit and Beck (2012:89), ethical considerations are systems of moral values 
that efforts to maintain high standards of integrity and avoid such forms of research 
misconduct as plagiarism, fabrication of results, or falsification of data. To comply with the 
expected ethical considerations, Ethical clearance (Annexure A) was obtained from the 
Research and Ethics Committee of the Department of Health Studies, University of South 
Africa and the researcher waited for the permission from the supervisor to proceed with data 
collection after the methodology chapter was approved. Permission to review the records 
was not necessary as all the studies were open access and obtained online from free 
websites. Data was collected and synthesised from from previous studies in which informed 
consent had already been obtained by the researchers. 
 
3.8 DATA ANALYSIS 
According to Paterson, Thorne, and Canam (2003:55-69) data-analysis in meta-analysis  
means the comparative analysis of research findings of primary research studies conducted  
by a variety of researchers. This is the analysis of “processed data” from selected research  
studies to create a systematically developed, integrated body of knowledge about a specific  
phenomenon. The process involved the comparison of each individual study with all other 
23 
 
 
 
studies that had a common focus. 
3.8.1 Validity and reliability of the data collection tool and the extracted  
 data 
According   to   Kimberlin   and   Winetrstein (2008:1)   measurement involves the 
operationalization  of  the  constructs  in  defined  variables  and  the  development and  
application of instruments or  tests  to  quantify  these  variables. The key indicators of the  
quality of a measuring instrument are the reliability and validity of the measures. The  
researcher used the following steps to improve the data collection tool and the extracted  
data: 
 
3.8.1.1 Reliability 
Reliability is the accuracy of an instrument or the extent to which a data collection tool 
consistently has the same results if it is used in the same situation on repeated occasions. To 
extract the findings from each study in a consistent manner, data were measured and 
collected consistently according to standard definitions and methodologies (Kimberlin & 
Winetrstein 2008:1-2). The researcher structured the data entry in a logical manner and was 
consistent in the order and style of description of the information for each included study. 
When constructing reliable data collection instruments the researcher: 
•   Ensured that the questions and the methodology are clear by using research steps  
 that are clearly explained and easy to follow for anyone to redo the procedure. 
•   Used explicit and straightforward definitions of concepts. 
•   Used already tested and proven Data Collection Form for RCTs & Non-RCTs from  
 the  Cochrane  Library,  available  from  http://airways.cochrane.org/resources-and- 
 information. The form was used as a guide for developing own data extraction form,  
 and permission to use the form was not necessary as all forms were open access  
 and obtained for free from Cochrane website. 
•   Was informed by the purpose of the study to develop the method of data extraction. 
•   Recorded any missing information as unclear or not described, to make it clear that  
 the information was not found in the study report(s). 
 
3.8.1.2 Validity 
According to Kimberlin and Winetrstein (2008:1), the extent to which the study can draw  
conclusions about the effects of an intervention depends on whether the data and results  
from the included studies are valid. In Polit and Beck (2012:34) the first dimension of validity 
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looks at the external validity and questions whether there is evidence to support the  
assertion that the methods are really measuring the abstract concepts that they purport to  
measure. The second dimension is the internal validity, relates to whether the study answers  
its  research  question ‘correctly’,  that  is,  in  a  manner  free  from  bias.  Kimberlin  and  
Winetrstein (2008:1), define validity as the extent to which a tool measures what it intends to  
measure. 
 
Validity requires that an instrument be reliable. Validity is not a property of the test itself.  
Instead, validity is  the  extent  to  which  the interpretations of the results of a test are  
warranted,  which  depends  on  the test’s measurement of the underlying construct  
(Kimberlin & Winetrstein 2008:4). This research involved quantifying attributes that could not  
be measured directly. Abstract concepts (constructs), such as treatment failure, health  
outcomes, and adherence to ARV regimens are measured. These constructs can only be  
inferred  from  observations  of  specific measurements that are  thought  to  be  indicators  
of  the presence of the construct. 
 
Likewise, in this study, treatment failure was measured as Viral load >400 copies/ml 6 
months after ART initiation or viral load rebound to > 400 copies/ml after documented full 
suppression. When constructing a valid data collection instruments the researcher: 
•   Ensured that the conceptual definitions were translated into operational definitions  
 that could be measured and quantified to enable the research instrument (or tool) to  
 measure the intended constructs. 
•   Carefully  considered  the  information  to  be  collected,  and  designed  the  form  
 accordingly in order to comprehensively and accurately measure all aspects of  
 concerned constructs. 
•   Specified key items for data extraction in advance in a data extraction template,  
 based on the participants, interventions, comparisons and outcomes of interest. 
•   Collected study aspects that could (or were believed to) affect the presence or  
 magnitude of an intervention effect and those that could help assess applicability. 
•   Used the collected data to address characteristics of included studies, risk of bias  
 assessment, and statistical analysis. 
•   Verified the data for accuracy and completeness on data transfer. 
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3.9 CONCLUSION 
This  chapter  presented  an  overview  of  the  research  design  and  methods.  The  next 
chapter presents analysis and description of the research findings. 
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CHAPTER 4 
ANALYSIS, PRESENTATION, AND DESCRIPTION OF  
 THE RESEARCH FINDINGS 
 
4.1 INTRODUCTION 
This chapter focuses on the data collection and analysis process and description of the  
study results. The chapter further addresses the characteristics of included studies and  
excluded studies,  followed  by  the  risk of bias in included studies and the effects of  
monitoring frequency. The findings are then discussed in line to the research objectives. 
 
4.2 DESCRIPTION OF STUDIES 
 
The relevant studies were described in detail under Characteristics of Studies (Annexure 
D) with the specific titles of "Characteristics of included studies" and "Characteristics of 
excluded studies". 
 
4.3 RESULTS OF THE SEARCH 
Results of the search for studies were organized and illustrated using study flow diagram 
generated in RevMan.  The Study flow diagram was used to illustrate the search outcome, 
and the process of screening and selecting studies for inclusion in this meta-analysis. 
4.3.1 Search outcomes 
From the search strategy (Annexure E), 860 titles were initially identified. After duplicates  
were removed, 681 citations remained to be screened. An initial single screen of these titles  
and abstracts, removed all titles which did not fit inclusion criteria, such as editorials, letters,  
clearly off topic studies. This initial single screening resulted in 668 studies being excluded.  
The inclusion criteria applied on the remaining 13 studies of which the full articles were  
obtained. Studies were reviewed for relevance, based on study design, types of participants,  
exposures, and outcomes measures. Of the 13 potentially relevant studies, eight met the  
inclusion criteria and were included in the review. The details of how the researcher  
ultimately excluded and included studies are displayed in the study flow diagram (Figure 
4.1). 
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Figure 4. 1 Flow diagram of eligibility criteria of studies 
4.3.2 Search yield 
In total, the researcher identified one randomised trial and seven observational studies with 
comparators for data extraction, coding, and potential meta-analysis. 
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4.4 INCLUDED STUDIES 
 
4.4.1 Randomized trials 
Weissman (2016) presents results from a randomised trial designed to determine the impact  
of changing scheduled follow up care for persons with HIV from a 4 to 6 months interval. It  
was conducted at an HIV clinic in South Carolina, USA on randomised patients who were  
followed for 18 months. A total of 165 patients, median age of 46.8 were randomised to two- 
study arms of the standard of care visit every 4 months versus the standard of care visits at 
6 months intervals. The primary outcome was virologic failure, which they defined as two 
successive VLs of >200 copies/ml. Secondary outcomes included the quality of life (QOL), 
and adherence. The study found no difference in virologic failure after 24 months between 
monitoring  every 4  months  versus  every 6  months.  For  stable,  HIV  VL  suppressed 
population less frequent HIV monitoring was safe during this short follow up. There was also no 
difference in QOL or adherence. 
 
4.4.2 Observational studies with comparators 
Seven observational studies met the inclusion criteria of this study. These studies aimed to  
evaluate a range of primary outcomes: time to detection of antiretroviral therapy (ART) failure  
(Bryant. 2012) and percentage of total person-years spent with virological failure (Schneider.  
2011), virological failure (Caniglia. 2016;Chaiwarith. 2011; Young. 2015), and treatment failure  
due to virological failures (Reekie. 2008; Romih. 2010). In resource-constrained settings, two  
studies were conducted in Thailand (Chaiwarith. 2011; Schneider. 2011), and one in Croatia  
(Romih. 2010). The other five cohort studies were based on high-income settings. Six studies  
included adults infected with HIV-1, and one study was based on data from a cohort of  
children (Schneider. 2011). In one study the comparison groups were plasma HIV-1 RNA  
monitoring at least thrice yearly versus plasma HIV-1 RNA monitoring twice yearly (Young.  
2015). The other six studies were more inclusive, the comparison groups were plasma HIV-1  
RNA monitoring at least twice yearly versus plasma HIV-1 RNA monitoring at most Once  
yearly. 
 
4.5 EXCLUDED STUDIES 
Five studies were excluded due to their irrelevance to the intervention or outcomes of 
interest as indicated in the 'Characteristics of excluded studies' table (Annexure D). 
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4.5.1 Randomized trials 
Haubrich et al (2001) presents results from a randomised trial designed to compare frequent  
measurement with infrequent measurement of human immunodeficiency virus (HIV) RNA  
levels in the management of antiretroviral therapy. The California Collaborative Treatment  
Group (CCTG) initiated a randomised clinical study from the primary care practices of 6  
university affiliated clinical sites. A group of 206 patients, above 18 years (interquartile range 
21 to 64, median 37) were randomised to two-study arms of the frequent group with ≥3 VLs  
performed per year versus the infrequent group with ≤2 VLs per year. The primary outcome  
was the area-based measure of viral suppression, the ACFB in HIV RNA levels. Secondary  
outcomes included the duration of undetectable virus load levels. The study found that, more  
frequent HIV RNA monitoring resulted in a reduction in virus load nearly twice than seen with  
less frequent virus load monitoring. Frequent HIV RNA monitoring resulted in near-doubling  
of the proportion and the duration of undetectable virus load levels. The study was excluded  
because it did not require individuals to be virologically suppressed at entry and did not look  
at treatment outcomes such as virologic failure, switch rates to second-line ART, adherence,  
and drug resistance measurements. 
4.5.2 Observational studies 
Braithwaite (2014) in an observational study describes the results of how different eligibility 
guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing. 
The  study  was  conducted  in  sub-Saharan  Africa,  and  the  primary  outcome  was  the 
incremental cost-effectiveness ratio (ICER). The study was excluded because it did not look at 
treatment outcomes such as virologic failure, switch rates to second-line ART, adherence, and 
drug resistance measurements. 
In Canada, Raboud (2010) conducted a study on regional differences in rates of HIV-1 viral 
load monitoring and their implications on antiretroviral care in high income countries. The 
primary outcome was the frequency of VL testing. The study was excluded because the 
outcome of interest is the frequency of VL monitoring, instead of clinical/health outcomes due 
to variations in frequency of VL testing. 
Rossouw (2017) conducted an observational study with comparators on patients who had  
failed a first-line NNRTI-based HAART regimen. The study was conducted in an urban and a  
rural setting in South Africa and the primary outcome was HIV-associated drug resistance 
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(HIVDR). It was excluded because all patients had failed a first-line NNRTI-based HAART  
regimen. 
 
Thirunavukarasu (2016) in a study conducted in South India reports on the patterns of HIV-1 
drug-resistance mutations among patients failing first-line antiretroviral treatment.  The 
outcome of interest was HIV-associated drug resistance. The study was excluded because it 
does not evaluate the frequency of viral load monitoring after initiation of ART; instead it 
evaluates the frequency and patterns of HIV-1 drug-resistance mutations. 
 
4.6 RISK OF BIAS IN INCLUDED STUDIES 
An assessment of the validity of studies included in this study emphasized the risk of bias in 
their results. The risk of bias was specifically assessed for both RCTs and observational 
studies. Risk of bias tables were generated, with support for the judgement on each entry 
addressing a specific feature of the study.  Detailed considerations for the assessment of 
these features are provided below. 
4.6.1  Randomised Control Trials 
The following apply to the one included randomised trial. Summaries of the assessment of the 
'Risk of bias' are depicted in Figure 4.2 and Figure 4.3. 
 
 
 
Random sequence generation (selection bias) 
Allocation concealment (selection bias) 
Blinding of participants and personnel (performance bias)  
 Blinding of outcome assessment (detection bias) 
Incomplete outcome data (attrition bias)  
 Selective reporting (reporting bias) 
Other bias 
 
0% 25% 50% 75% 100% 
 
Low risk of bias Unclear risk of bias High risk of bias 
 
 
Figure 4. 2 Risk of bias graph: review researcher's judgements about each risk of bias 
item presented as percentages across all included studies. 
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Bryant. 2012 ? ? ? ? ? ? ? 
Caniglia. 2016 ? ? ? ? ? ? ? 
Chaiwarith. 2011 ? ? ? ? ? ? ? 
Reekie. 2008 ? ? ? ? ? ? ? 
Romih. 2010 ? ? ? ? ? ? ? 
Schneider. 2011 ? ? ? ? ? ? ? 
Weissman. 2016 + + ? ? ? + + 
Young. 2015 ? ? ? ? ? ? ? 
 
 
Figure 4. 3 Risk of bias summary: review authors' judgements about each risk of bias 
item for each included study. 
 
 
•   Allocation (selection bias) 
Generation of the allocation sequence and concealment of allocation was adequately  
performed in the trial (Weissman. 2016), and patients infected with HIV were randomized  
into 1 of 2 groups, that is, every 4 months monitoring (Group I) or 6 month monitoring (Group  
II). Baseline characteristics did not differ between the groups. The Weissman (2016) trial did  
describe details of allocation concealment. No systematic differences between groups in the  
care  that  was  provided,  and  the  standard  care  included:  medical  provider  visits  and 
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laboratory monitoring, which included CD4 county and VL among others. 
 
 
•   Blinding (performance bias and detection bias) 
No information was available for Weissman (2016) on blinding. It is unclear if either the 
outcome assessors or patient participants were blinded. Non-blinding was not likely to 
introduce bias. 
 
•   Incomplete outcome data (attrition bias) 
No information was available for Weissman (2016) on incomplete outcome data due to loss to 
follow-up. 
 
•   Selective reporting (reporting bias) 
The trial by Weissman (2016) appeared to be free of selective reporting. The outcomes 
mentioned in the methods sections were reported in the results sections. 
 
•   Other potential sources of bias 
The trial by Weissman (2016) appeared to be free of other potential sources of bias, and there 
are no clear sources for other potential bias. 
4.6.2 Observational studies 
Seven observational studies (Bryant. 2012; Caniglia. 2016; Chaiwarith. 2011; Reekie. 2008;  
Romih. 2010;  Schneider. 2011;  Young. 2015)  were  included  in  the  final  analysis  of  
observational studies characteristics and methodological quality as shown in Table 4.1. 
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Table 4. 1 Newcastle-Ottawa quality assessment scale for included observational  
studies 
 
ITEM 
 Bryant. 
2012 
 Schneider. 
2011 
 Chaiwarith. 
2011 
 Romih. 
2010 
 Reekie. 
2008 
 Caniglia. 
2016 
 Young. 
2015 
Representativeness of 
Cohort 
  
1 
  
1 
  
1 
  
1 
  
1 
  
1 
  
0 
Selection of Non-exposed 
Cohort 
  
0 
  
1 
  
0 
  
1 
  
0 
  
1 
  
1 
Ascertainment of Cohort 0 1 0 0 1 0 1 
Outcome of Interest Not 
Present at Start of Study 
  
1 
  
1 
  
0 
  
1 
  
1 
  
0 
  
0 
Comparability of Cohorts 1 1 1 0 1 1 1 1 
Comparability of Cohorts 2 1 1 0 1 0 1 1 
Assessment of Outcome 1 0 0 1 1 1 1 
Long Enough Follow-up 1 1 0 1 0 1 1 
Adequacy of Follow-up 1 1 0 0 0 0 1 
TOTAL 7 8 1 7 5 6 7 
 
4.7 EFFECTS OF INTERVENTIONS 
All eight studies evaluated the effects of different frequencies of VL monitoring on virological  
outcomes (Caniglia 2016; Chaiwarith 2011; Reekie 2008; Romih 2010; Weissman 2016)  
reported the virological outcome as Virological failure. The cut-off for viral load suppression  
was reported at different levels in each of the studies with (Caniglia 2016; Young 2015)  
considering virologic failure as HIV RNA ≥200 copies/mL, and in Weissman (2016) virologic  
failure was defined as two successive VLs of ≥200 copies/ml. Of the evidence available, two  
comparisons were studied; namely, frequent testers of ≥3 VLs per year versus less frequent  
testers of ≤2 VLs per year;  and frequent testers of ≥2 VLs per year versus less frequent  
testers of ≤1 VLs per year. 
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4.7.1  Comparison 1: Frequent testers (≥3 vls per year) versus less  
 frequent testers (≤2 vls per year) 
Based upon five studies including 10,695 patients, the risk of VL failure in the ≥3 VLs per  
year monitoring strategy is not different at all when compared with the risk of VL failure in a  
less frequent (≤2 VLs per year) monitoring strategy (RR 1.00, 95% CI 0.80 to 1.25).  
Significant statistical heterogeneity was found for the outcome of VL failure (I2=84%,  
p=0.0001) as shown in Figure 4.4 (Analysis 1.1). Only one trial reported on adherence  
(Weissman. 2016). This study found no difference in adherence scores of the two study  
arms, (SMD 0.00, 95% CI -0.33 to 0.33) as shown in Figure 4.5 (Analysis 1.2). 
4.7.2 Comparison 2: Frequent testers (≥2 VLs per year) versus less  
 frequent testers (≤1 VLs per year) 
Based upon four studies including 6,329 patients, ≥2 VLs per year monitoring the results in  
reduced VL failure, compared with less frequent monitoring of ≤1 VLs per year, and RR 1.82,  
95% CI 1.43 to 2.30 as shown in Figure 4.6 (Analysis 2.1). The ≥2 VLs per year monitoring  
led to a reduction in percentage of total person-years spent with virological failure (data from  
Schneider 2011 only). (MD 32.00, 95% CI 13.97 to 50.03) as shown in Figure 4.7 (Analysis 
2.2). The ≥2 VLs per year monitoring results in reduction of the time for the detection of 
virologic failure (data from Bryant 2012 only, (MD 0.80, 95% CI 0.69 to 0.91) as shown in 
Figure 4.8 (Analysis 2.3). 
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Figure 4. 4 (Analysis 1.1) Forest plot of comparison: 1 Frequent monitoring (≥3 VLs per year) versus less frequent monitoring (≤2 
VLs per year), outcome: 1.1 Virologic failure. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 5 (Analysis 1.2) Forest plot of comparison: 1 Frequent monitoring (≥3 VLs per year) versus less frequent monitoring (≤2 
VLs per year), outcome: 1.2 Adherence scores. 
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Figure 4. 6 (Analysis 2.1) Forest plot of comparison: 2 Frequent monitoring (2 VLs per year) versus less frequent monitoring (≤1 
VLs per year), outcome: 2.1 Virologic failure. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 7 (Analysis 2.2) Forest plot of comparison: 2 Frequent monitoring (2 VLs per year) versus less frequent monitoring (≤1 
VLs per year), outcome: 2.2 median time for the detection of virologic failure. 
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Figure 4. 8 (Analysis 2.3) Forest plot of comparison: 2 Frequent monitoring (2 VLs per year) versus less frequent monitoring (≤1 
VLs per year), outcome: 2.3 Percentage of total person-years spent with virological failure. 
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4.8 DATA AND ANALYSIS TABLES 
 
 
 
 
Table 4. 2 Frequent monitoring (≥3 VLs per year) versus less frequent monitoring (≤2 VLs per year) 
 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
1.1 Virologic failure 5 10695 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.80, 1.25] 
1.2 Adherence scores 1 142 Std. Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.33, 0.33] 
 
 
 
 
Table 4. 3 Frequent monitoring (2 VLs per year) versus less frequent monitoring (≤1 VLs per year) 
 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
2.1 Virologic failure 4 6329 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [1.43, 2.30] 
2.2 median time for the detection of virologic failure 1 626 Mean Difference (IV, Fixed, 95% CI) 32.00 [13.97, 50.03] 
2.3 Percentage of total person-years spent with 
virological failure 
 
1 
 
608 
 
Mean Difference (IV, Fixed, 95% CI) 
 
0.80 [0.69, 0.91] 
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4.9 CONCLUSION 
In this chapter data were collected from eight studies and analysed using meta-analysis 
method. Two comparison groups emerged from the study being; frequent monitoring (≥3 VLs 
per year) versus less frequent monitoring (≤2 VLs per year) and frequent monitoring (2 VLs per 
year) versus less frequent monitoring (≤1 VLs per year). The next chapter presents the conclusion 
and recommendations. 
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CHAPTER 5 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 INTRODUCTION 
The objective of this chapter is to provide the summary of the findings, applicability of 
evidence, recommendations for practice and research. 
 
5.2 SUMMARY OF MAIN RESULTS 
Despite  a  comprehensive  search,  a  limited  number  of  studies  were  identified  which  
addressed this topic, and, of the one randomised trial identified, evaluated the primary  
outcome of interest, virologic failure. Observational studies were also limited in number and  
they were of good quality. Of the seven observational studies identified, one was in abstract  
form only when the literature search was conducted. There appeared to be substantial value  
to clinical care for key outcomes; namely, virological failure and median time for the  
detection of virologic failure favouring a monitoring strategy with frequency of 2 VLs per year  
versus either ≥3 VLs per year or ≤1 VLs per year. Evidence from the seven observational  
studies and one randomised trial found no difference in virologic failure between the frequent  
monitoring of ≥3 VLs per year and the less frequent monitoring of 2 VLs per year .Therefore,  
in this study, VL monitoring in adherent patients with a stable undetectable VL can be  
reasonably extended from 3 months to every 6 months. The findings from the observational  
studies alone suggest that a monitoring strategy of ≤1 VLs per year increases the risk of  
virologic failure compared with monitoring every 6 months. Most of the included studies did  
not report on adherence, however, there is no indication that frequent monitoring would  
improve patient adherence. 
In Weissman (2016) a randomised trial that evaluated virologic failure, there were no  
differences seen in the risk of virologic failure when comparing ≥3 VLs per year and 2 VLs  
per year. While 2 VLs per year monitoring strategy appears to have benefits in early  
detection of virological failure and reducing the risk of failure compared to ≤1 VLs per year  
monitoring strategy, there remain many areas of uncertainty. For example, there remains no  
standardised definition for VL failure in the included studies. In Caniglia (2016) and Young  
(2015) virologic failure was defined as HIV RNA ≥200 copies/mL, in contrast to the study by 
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Weissman (2016) where virologic failure was defined as two successive VLs of ≥200 
copies/ml. 
Further complicating the standard of VL failure is that in Bryant (2012) virologic failure was  
defined as HIV-1 RNA > 400 copies/mL, after previously having achieved viral suppression.  
In Schneider (2011) virologic failure was defined as increased plasma HIV RNA to at least  
1000 RNA copies/ml after having previously undetectable viral load. Due to the different  
standards of VL failure, the estimates of effect from Bryant (2012) and Schneider (2011)  
could not be combined into a summary estimate as their patients are not virologically  
suppressed based on the standards of the other studies (Caniglia 2016; Young 2015;  
Weissman 2016). 
The benefit of the 2 VLs per year monitoring strategy must also be considered in the context of 
its associated costs. Most of the included studies relied on clinical cohorts based on high- 
income countries and thus these data may indirectly or partially generalizable to resource- 
limited settings. In this study, the researcher did not assess the costs that may be associated 
with the different monitoring frequencies. One of the included observational studies (Bryant 
2012) compared the cost of Frequent testing of ≥2 VLs per year versus less frequent testing of 
≤1 VLs per year; and found that the cost of reduced monitoring scheme of ≤1 VLs per year 
would be significantly less than the 2 VLs per year monitoring scheme. The 2 VLs per year 
monitoring resulted in the reduction of the time to detect virologic failure when compared 
with the reduced monitoring scheme of ≤1 VLs per year. 
While a statistically significant difference was shown; it  was  not necessarily clinically 
significant (Bryant et al 2013:3). In low-income settings where monitoring ART is based on 
CD4 counts only, using a reduced monitoring scheme can add value to clinical care with 
minimal added costs. Monitoring of viral loads in low-income settings with a reduced 
sampling scheme such as the one in Bryant (2012), where VLs are performed at certain 
interval like 6, 36, and 60 months, is a promising variant of virologic monitoring in need of 
further evaluation in a randomised control study. In such a randomised trial, patients would be 
randomised to receive standard viral load testing every 6 months or to one or more reduced 
viral load-monitoring schemes. The aim would be to monitor subjects for virological failure and 
determine whether the use of a reduced sampling scheme in low-income settings would be 
equally effective at a lower cost than standard testing. The primary outcome, virologic 
failure, would be measured between the groups. 
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This study findings support the current WHO recommendations for biannual VL monitoring  
among clinically stable and virologically suppressed HIV-infected patients. VL monitoring at 
2 VLs per year monitoring frequency was not associated with increased rates of virologic 
failure and could generate substantial financial cost savings without jeopardizing patient 
safety, freeing the resources to expand, and improve other aspects of HIV care. 
5.3 OVERALL COMPLETENESS AND APPLICABILITY OF  
 EVIDENCE 
The eight studies included, evaluate effects of different monitoring frequencies used to 
monitor virologically suppressed patients, which limits the researcher's ability to make 
broad generalizations on patients who are not necessarily suppressed. A trial by Haubrich et 
al (2001:6), that did not require individuals to be virologically suppressed at entry, had a study 
population predominately with a low CD4 cell count and had HIV-1 RNA levels of ≥5000 
copies/mL. the study found that frequent monitoring of HIV RNA levels, perhaps as often as 
every 2 months, may be necessary to detect loss of virological suppression and adjust 
therapy accordingly (Haubrich et al 2001:7). 
 
5.4 QUALITY OF THE EVIDENCE 
The overall quality of evidence in the eight studies included in this meta-analysis is  
moderate, as described earlier in section 4.6 for the "RISK OF BIAS IN INCLUDED  
STUDIES".  Only  one  was  a  randomised  controlled  trial  and  the  other  seven  were  
observational studies and therefore introduced selection bias. The randomised study had a  
small sample size and a relatively short follow up time. While the findings are interesting  
and informative, it is important to note that they are reliant on observational studies and  
one small randomised trial. The utilization of data published in observational studies may  
not represent the full picture on causality. The primary reason for downgrading the quality  
of  evidence  was  'indirectness',  the  researcher  had  only  one  trial  to  make  broad  
generalizations  about  the  potential  effects.  Publication  bias  was  minimized  by  a  
comprehensive  search  strategy  that  included  evaluating  published  and  unpublished  
literature. 
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5.5 AGREEMENTS AND DISAGREEMENTS WITH OTHER  
 STUDIES OR REVIEWS 
 
There  is  one  randomised  clinical  trial  (Haubrich  et  al  2001:7)  comparing  frequent  
measurement with infrequent measurement of human immunodeficiency virus (HIV) RNA  
levels in the management of antiretroviral therapy. A closer inspection of this trial indicates  
that it did not require individuals to be virologically suppressed at entry. This trial was not  
included in this meta-analysis because its eligibility criteria on the types of participants and  
outcome measures were inconsistent with the included studies. The failure of the studies  
included in this meta-analysis to find a benefit of ≥3 VLs per year versus 2 VLs per  
year)monitoring is in disagreement with the findings of this excluded trial (Haubrich et al  
2001:7). With an exception of Haubrich et al (2001), there are no other studies or  
systematic reviews addressing this topic that the researcher is aware of at this time. 
 
5.6 CONCLUSIONS 
 
5.6.1 Recommendations for practice 
Evidence in this meta-analysis supports the use of  2 VLs per year as the optimal 
monitoring strategy for stable, HIV VL suppressed adult population and there is nothing to be 
gained by a more frequent monitoring of ≥3 VLs per year. However, further cost- 
analysis studies are necessary to solidify these findings and make conclusions about the long 
term applicability of this strategy to low-resource settings. It is not known whether the use of 2 
VLs per year monitoring strategy on patients who are not virologically suppressed and 
unstable, could be safe for patients. More research should be conducted on similar 
interventions  to  address  patients  who  are  not  virologically  suppressed,  in  resource 
constrained countries, and be inclusive of children. 
 
5.6.2 Recommendations for research 
Only  one  trial  evaluated  the  effects  of  different  monitoring  frequencies  on  virologic  
response. The trial was conducted in developed countries, in adult population, and all  
included patients had sustained virologic suppression. The "Test and Teat" strategy will  
include patients, regardless of CD4 and viral load status, and subsequently having healthy  
individuals being enrolled for ART. Therefore monitoring frequency reduction studies in  
healthy, HIV positive patients may be warranted if "Test and Treat" strategy is universally 
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rolled-out. Randomized controlled trials investigating the efficacy and safety of ≤1 VLs per  
year in ART patients enrolled through the "Test and Treat" strategy are needed. Given the  
evidence that ≤1 VLs per year may be unsafe for patients, it is unlikely that a clinical trial  
for such a monitoring frequency would be acceptable to some researchers and people  
affected by HIV. Therefore such a trial will require much innovation including education of  
people affected by HIV. 
 
5.7 CONTRIBUTIONS OF THE STUDY 
These study findings contribute to the body of knowledge to better understand optimal  
virologic monitoring frequencies for HIV-1 infected individuals. Furthermore, the findings  
contribute towards evidence-based medical decisions with regards to optimal frequency of  
viral load monitoring. As a way of dissemination of information, the researcher will present  
the study at conferences to report and share the research finding with other researchers  
and concerned communities at large. The study findings will also be published in the  
relevant academic journals to increase the dissemination of the body of knowledge. 
 
5.8 LIMITATIONS OF THE STUDY 
The findings of this meta-analysis favour a virologic monitoring frequency of every 6  
months; however, they are highly reliant on a single trial and seven observational studies.  
It is necessary to have further trials from other settings evaluating VL failure as a primary  
outcome of different monitoring frequencies and a standardised virologic failure defined as  
HIV-1 RNA ≥400 copies/mL after previously having achieved viral suppression. To validate  
the findings of this meta-analysis, larger RCTs with longer follow up time should be  
conducted.  Two  of  the  studies (Bryant. 2012;  Schneider. 2011)  assessed  different  
outcomes and did not assess VL failure. Because of heterogeneity in the types of  
outcomes, the researcher was unable to pool data from the two studies for meta-analysis.  
There is a need to introduce an affordable, feasible and sustainable system for viral load  
monitoring in resource limited contexts aimed at all patients including disadvantaged  
group. It is also important to note that the included trial (Weissman. 2016) did not include  
children, and only one observational study (Schneider. 2011) included children but did not  
evaluate the VL failure as an outcome. Children could therefore be an important group for  
further research. The sample size was relatively small. 
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5.9 CONCLUDING REMARKS 
In conclusion, several studies evaluating the effects of different VL monitoring frequencies  
on viorologic response have been conducted to date. The differences in their results are  
largely due to differences in their definition of Virologic failure, and what they consider  
frequent or infrequent monitoring. Only by standardising and controlling for these can the  
effects of VL monitoring be studied in detail. Therefore, there is need to adopt standardised  
cut off points for virologic failure. Overall, this meta-analysis supports the use of 2 VLs per  
year as the optimal monitoring strategy for stable, HIV VL suppressed adult population. 
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Study eligibility criteria 
 
Study 
Characteristics 
Eligibility criteria Eligibility criteria met? Decision 
(INCLUDE 
or 
EXCLUDE)) 
 
Yes No   Unclear 
Language of 
study 
English  INCLUDE if 
it’s YES only 
Type of study Randomised Controlled Trial        INCLUDE 
 
Quasi-randomised Controlled 
Trial 
 INCLUDE 
 Other design (specify):  INCLUDE 
 Letter, editorial, non-systematic 
review, observational studies 
without comparators, case 
report, cross-sectional study 
design, or descriptive studies 
 INCLUDE if 
it’s NO only 
Participants Populations include ARV-naive, 
ARV-experienced or a 
combination of these without 
restriction on age, ethnicity, 
race, and nationality. 
 INCLUDE if 
it’s YES only 
 Population of HIV-1 infected 
patients that were initially 
virologically well suppressed, 
on ART 
 INCLUDE if 
it’s YES only 
 Studies evaluating ART in 
patients who have not failed 
any treatment regimen 
 INCLUDE if 
it’s YES only 
Types of 
intervention 
Study must evaluate the 
frequency of viral load 
monitoring after initiation of 
ART 
 INCLUDE if 
it’s YES only 
Types of 
comparison 
Less frequent (≤2 VLs per year) 
versus more frequent (≥3 VLs 
per year) virologic monitoring 
 INCLUDE if 
it’s YES only 
 
   
            
   
                  
   
             
                 
       
     
   
 
 
 
Types of Study should have treatment INCLUDE if 
outcome outcomes such as virologic it’s YES only 
measures failure, switch rates to second- 
line ART, adherence, and drug 
resistance measurements 
Studies evaluating switching INCLUDE if 
ART due to clinical, it’s YES only 
immunologic, or virologic failure 
rather than substituting ART 
due  to toxicities 
 
 
First-line drug ART that must include either a INCLUDE if 
regimen details NNRTI or PI as part of their it’s YES only 
treatment regimen. 
INCLUDE EXCLUDE 
Reason for  
exclusion 
 
 
Notes: 
 
 
 
 
DO NOT PROCEED WITH THE STUDY IF IT’S EXCLUDED 
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DATA COLLECTION FORM 
 
 
 
 
General Information 
 
Date form completed (dd/mm/yyyy)  
Name/ID of Reviewer extracting data  
Study title 
(title of paper/ abstract/ report that data are extracted from) 
 
Study ID (surname of first author and year first full report of study 
was published)) 
 
Publication type 
(e.g. full report, abstract, letter) 
 
Study funding source 
(including role of funders) 
 
Possible conflicts of interest 
(for study authors) 
 
Notes: 
Eligibility 
 
Study 
Characteristics 
Review Inclusion Criteria 
(Insert inclusion criteria for each 
characteristic as defined in the 
Protocol) 
 
 
 
 
Yes/ No / Unclear 
Location in text 
(pg & /fig/table) 
  
 
 
 
 
 
Study 
Characteristics 
Review Inclusion Criteria 
(Insert inclusion criteria for each 
characteristic as defined in the 
Protocol) 
 
 
 
 
Yes/ No / Unclear 
Location in text 
(pg & /fig/table) 
Type of study Randomised trial   
Non-randomised trial   
Other design (specify):   
Participants    
Types of intervention    
Types of outcome 
measures 
   
Decision: 
Reason for exclusion  
Notes 
 
WILL NOT PROCEED IF STUDY IS EXCLUDED FROM REVIEW 
Population and setting 
 
 
 
 
 
 
 Description 
Include comparative information for 
each group (i.e. intervention and 
controls) if available 
Location in text 
(pg & /fig/table) 
Population description 
(from which study participants 
are drawn) 
  
Setting 
(including location and social 
context) 
  
Inclusion criteria   
Exclusion criteria   
Method/s of recruitment of 
participants 
  
Methods 
 
 Descriptions as stated in 
report/paper 
Location in text 
(pg & /fig/table) 
Aim of study   
 
 
 
 
 
Design 
(e.g. parallel, crossover, non- 
RCT) 
  
Unit of allocation 
(by individuals, cluster/ groups) 
  
Start date   
End date   
Duration of participation 
(from recruitment to last follow- 
up) 
  
Notes: 
 
 
Risk of Bias assessment 
 
Domain Risk of bias 
Low/ High/Unclear 
Support for 
judgement 
Location in text 
(pg & /fig/table) 
Random sequence generation 
(selection bias) 
   
Other potential threats to 
validity (performance bias) 
   
 
 
 
 
 
Domain Risk of bias 
Low/ High/Unclear 
Support for 
judgement 
Location in text 
(pg & /fig/table) 
Blinding of outcome 
assessment 
(detection bias) 
   
Incomplete outcome data 
(attrition bias) 
   
Selective outcome reporting? 
(reporting bias) 
   
Other bias    
Notes: 
Participants 
 
 
 
 Description as stated in report/paper Location in text 
(pg & /fig/table) 
Population size   
Baseline imbalances   
Withdrawals and exclusions   
 
 
 
 
 
 Description as stated in report/paper Location in text 
(pg & /fig/table) 
Median age in years   
Sex   
Race/Ethnicity   
First-line drug regimen details   
Population HIV prevalence   
Other relevant socio- 
demographics 
  
Subgroups measured   
Subgroups reported   
Intervention groups  
Intervention Group 1 
 Description as stated in report/paper Location in text 
(pg & /fig/table) 
Group name   
Group size   
Duration of monitoring period   
 
 
 
 
 
 Description as stated in report/paper Location in text 
(pg & /fig/table) 
Timing 
(frequency of monitoring) 
  
Co-interventions   
Notes: 
 
 
Intervention Group 2 
 
 Description as stated in report/paper Location in text 
(pg & /fig/table) 
Group name   
Group size   
Duration of monitoring period   
Timing 
(frequency of monitoring) 
  
Co-interventions   
Notes: 
  
 
Outcomes  
Outcome 1 
 
 Description as stated in report/paper Location in text 
(pg & /fig/table) 
Outcome name   
Time points measured 
(specify whether from start or 
end of intervention) 
  
Outcome definition 
(with diagnostic criteria if 
relevant and note whether the 
outcome is desirable or 
undesirable if this is not 
obvious) 
  
Unit of measurement 
(if relevant) 
  
Is outcome validated?  
Yes/No/Unclear 
  
Notes: 
   
 
  
 
 
 
 
Results 
For randomised or non-randomised study - Dichotomous outcome 
 
 Description as stated in report/paper Location in text 
(pg & /fig/table) 
Outcome   
Time point 
(specify whether from start or 
end of intervention) 
  
Results ≥3 VLs per year ≤2 VLs per year  
No. events No. participants No. events No. participants  
    
Baseline data ≥3 VLs per year ≤2 VLs per year  
No. events No. participants No. events No. participants  
    
 
 
 
 
 
 
 Description as stated in report/paper Location in text 
(pg & /fig/table) 
Effect sizes (Cohen’s d, odds 
ratio, risk ratio 
Or data allowing to estimate 
effect sizes 
-e.g. mean + SD + n in each 
group, results of a statistical 
test) 
  
Notes: 
For randomised or non-randomised study - Continuous outcome 
 
 Description as stated in report/paper Location in 
text 
(pg & /fig/table) 
Outcome   
Time point   
Post-intervention or change 
from baseline? 
  
Results ≥3 VLs per year ≤2 VLs per year  
  
  
  
 
 
 
 
 
 Description as stated in report/paper Location in 
text 
(pg & /fig/table) 
 Mean SD (or 
other 
variance) 
No. 
participants 
Mean SD (or other 
variance) 
No. participants  
      
Baseline data ≥3 VLs per year ≤2 VLs per year  
Mean SD (or 
other 
variance) 
No. 
participants 
Mean SD (or other 
variance) 
No. participants 
      
Effect sizes (Cohen’s d, odds 
ratio, risk ratio Or data 
allowing to estimate effect 
sizes -e.g. mean + SD + n in 
each group, results of a 
statistical test) 
  
Notes: 
For randomised or non-randomised study - Other outcome 
 
 Description as stated in report/paper Location in text 
 
  
  
  
  
 
 
 
 
 
 Description as stated in report/paper Location in text 
Outcome   
Type of outcome   
Results ≥3 VLs per year 
result 
SD (or other 
variance) 
≤2 VLs per year SD (or 
other 
variance) 
 
    
Overall results SE (or other variance) 
  
No. participant ≥3 VLs per year ≤2 VLs per year  
  
Effect sizes (Cohen’s d, odds 
ratio, risk ratio Or data 
allowing to estimate effect 
sizes -e.g. mean + SD + n in 
each group, results of a 
statistical test) 
  
Notes: 
 
 
 
 
 
Applicability 
 
Have important populations been excluded from 
the study? 
(consider disadvantaged populations, and 
possible differences in the intervention effect) 
 
Yes/No/Unclear 
 
Is the intervention likely to be aimed at 
disadvantaged groups? 
(e.g. lower socioeconomic groups) 
 
Yes/No/Unclear 
 
Does the study directly address the review 
question? 
(any issues of partial or indirect applicability) 
 
Yes/No/Unclear 
 
Notes: 
Other information 
 
 Description as stated 
in report/paper 
Location in text 
(pg & /fig/table) 
Key conclusions of study authors   
limitations   
Generalisability   
Further study information requested  
 
 
 
 
ANNEXURE D: 
 
 
CHARACTERISTICS OF STUDIES 
 
 
 
1. CHARACTERISTICS OF INCLUDED STUDIES 
 
 
 
 
Bryant. 2012 
Methods Cohort Study with Kaplan-Meier Survival analysis 
Participants ARV naive, HIV-1-infected patients treated with zidovudine (ZDV), lamivudine (3TC), and efavirenz 
(EFV). 
Interventions Viral load at baseline and every 6 months versus reduced viral load monitoring with CD4 count at 
baseline and viral load testing at 6, 36, and 60 months 
Outcomes Median time for the detection of virologic failure 
 
 
 
 
 
 
Risk of bias table: Bryant. 2012 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk N/A, see Table 1. 
Allocation concealment (selection bias) Unclear risk N/A, see Table 1. 
Blinding of participants and personnel (performance bias) Unclear risk N/A, see Table 1. 
Blinding of outcome assessment (detection bias) Unclear risk N/A, see Table 1. 
Incomplete outcome data (attrition bias) Unclear risk N/A, see Table 1. 
Selective reporting (reporting bias) Unclear risk N/A, see Table 1. 
Other bias Unclear risk N/A, see Table 1. 
 
 
 
 
 
Caniglia. 2016 
Methods Cohort Study with a Parallel design 
Participants Antiretroviral-naive individuals who initiated ART and became virologically suppressed within 12 
months were followed from the date of suppression. 
Interventions HIV-RNA monitoring strategies: once every (3±1 months);(6 ±1 months);(9-12 ± 1 months) 
Outcomes virologic failure 
 
 
Risk of bias table: Caniglia. 2016 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk N/A, see Table 1. 
Allocation concealment (selection bias) Unclear risk N/A, see Table 1. 
Blinding of participants and personnel (performance bias) Unclear risk N/A, see Table 1. 
Blinding of outcome assessment (detection bias) Unclear risk N/A, see Table 1. 
Incomplete outcome data (attrition bias) Unclear risk N/A, see Table 1. 
Selective reporting (reporting bias) Unclear risk N/A, see Table 1. 
Other bias Unclear risk N/A, see Table 1. 
 
 
Chaiwarith. 2011 
Methods Retrospective Observational Cohort Study 
Participants HIV-infected patients on a stable regimen 
Interventions frequency of monitoring of the stable patients 
Outcomes virological failure and number of reverse transcriptase (RT) mutations 
Notes Abstract only 
 
 
Risk of bias table: Chaiwarith. 2011 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk N/A, see Table 1. 
Allocation concealment (selection bias) Unclear risk N/A, see Table 1. 
Blinding of participants and personnel (performance bias) Unclear risk N/A, see Table 1. 
Blinding of outcome assessment (detection bias) Unclear risk N/A, see Table 1. 
Incomplete outcome data (attrition bias) Unclear risk N/A, see Table 1. 
Selective reporting (reporting bias) Unclear risk N/A, see Table 1. 
Other bias Unclear risk N/A, see Table 1. 
 
 
 
 
 
Reekie. 2008 
Methods Prospective cohort study 
Participants All included patients from EuroSIDA were on a stable and fully suppressed cART regimen for a 
period of 1 year 
Interventions frequency of monitoring of the stable patients 
Outcomes Risk of treatment failure 
 
 
Risk of bias table: Reekie. 2008 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk N/A, see Table 1. 
Allocation concealment (selection bias) Unclear risk N/A, see Table 1. 
Blinding of participants and personnel (performance bias) Unclear risk N/A, see Table 1. 
Blinding of outcome assessment (detection bias) Unclear risk N/A, see Table 1. 
Incomplete outcome data (attrition bias) Unclear risk N/A, see Table 1. 
Selective reporting (reporting bias) Unclear risk N/A, see Table 1. 
Other bias Unclear risk N/A, see Table 1. 
 
 
Romih. 2010 
Methods retrospective cohort study 
Participants ART naive patients who were initially well suppressed and considered fully adherent during the first 
15 months of CART 
Interventions different viral load monitoring frequencies 
Outcomes CART failure 
 
 
Risk of bias table: Romih. 2010 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk N/A, see Table 1. 
Allocation concealment (selection bias) Unclear risk N/A, see Table 1. 
Blinding of participants and personnel (performance bias) Unclear risk N/A, see Table 1. 
Blinding of outcome assessment (detection bias) Unclear risk N/A, see Table 1. 
Incomplete outcome data (attrition bias) Unclear risk N/A, see Table 1. 
Selective reporting (reporting bias) Unclear risk N/A, see Table 1. 
Other bias Unclear risk N/A, see Table 1. 
 
 
 
 
 
 
 
 
Schneider. 2011 
Methods Cohort study 
Participants 304 ARV naive, HIV-1-infected patients 
Interventions different viral load monitoring frequencies 
Outcomes costs and clinical outcomes 
 
 
Risk of bias table: Schneider. 2011 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk N/A, see Table 1. 
Allocation concealment (selection bias) Unclear risk N/A, see Table 1. 
Blinding of participants and personnel (performance bias) Unclear risk N/A, see Table 1. 
Blinding of outcome assessment (detection bias) Unclear risk N/A, see Table 1. 
Incomplete outcome data (attrition bias) Unclear risk N/A, see Table 1. 
Selective reporting (reporting bias) Unclear risk N/A, see Table 1. 
Other bias Unclear risk N/A, see Table 1. 
 
 
Young. 2015 
Methods Observational Cohort Study 
Participants Antiretroviral-naive individuals who initiated ART and became virologically suppressed within 12 
months were followed from the date of suppression. 
Interventions frequency of VL testing 
Outcomes virologic failure (VF), defined as at least 1 VL≥200 copies/mL during the 2-year followup period after 
the index date 
 
 
Risk of bias table: Young. 2015 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection bias) Unclear risk N/A, see Table 1. 
Allocation concealment (selection bias) Unclear risk N/A, see Table 1. 
Blinding of participants and personnel (performance bias) Unclear risk N/A, see Table 1. 
Blinding of outcome assessment (detection bias) Unclear risk N/A, see Table 1. 
Incomplete outcome data (attrition bias) Unclear risk N/A, see Table 1. 
Selective reporting (reporting bias) Unclear risk N/A, see Table 1. 
Other bias Unclear risk N/A, see Table 1. 
 
 
 
 
 
 
 
 
Weissman. 2016 
Methods Randomized controlled trial(RCT) 
Participants HIV positive patients who are on cART and on PI based regimen and on a non-nucleoside regimen 
Interventions frequency of monitoring of the stable patients 
Outcomes VL failure, quality of life, and adherence 
 
 
Risk of bias table: Weissman. 2016 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection bias) Low risk Patients were randomized to every 4 months 
monitoring (Group I) or 6 month monitoring 
(Group II). Baseline characteristics did not 
differ between the groups. 
Allocation concealment (selection bias) Low risk Standard care included: medical provider visits 
and laboratory monitoring, which included CD4 
county and VL among others. 
Blinding of participants and personnel (performance bias) Unclear risk Not reported. 
Blinding of outcome assessment (detection bias) Unclear risk Not reported. 
Incomplete outcome data (attrition bias) Unclear risk Not reported. 
Selective reporting (reporting bias) Low risk The primary outcome was the same as in the 
one reported 
Other bias Low risk  
   
     
     
   
     
     
   
     
     
   
     
     
   
     
     
 
 
 
2. Characteristics of excluded studies 
 
 
 
Braithwaite. 2014 
Study did not look at treatment outcomes such as virologic failure, switch rates to second-line ART, adherence, 
Reason for exclusion and drug resistance measurements 
 
 
 
Haubrich. 2001 
Study did not require individuals to be virologically suppressed at entry and did not look at treatment outcomes 
Reason for exclusion  such as virologic failure, switch rates to second-line ART, adherence, and drug resistance measurements 
 
 
 
Raboud. 2010 
The outcome of interest is the frequency of VL monitoring, instead of clinical/health outcomes due to variations 
Reason for exclusion in frequency of VL testing 
 
 
Rossouw. 2017 
Reason for exclusion  All patients had failed a first line NNRTI-based HAART regimen 
 
 
Thirunavukarasu. 2016 
Study does not evaluate the frequency of viral load monitoring after initiation of ART, instead it evaluates the 
Reason for exclusion frequency and patterns of HIV-1 drug-resistance mutations 
 
 
 
 
 
ANNEXURE E 
 
 
 
 
 
SEARCH STRATEGIES AND RESULTS 
 
 
 
Table 1: Summary of Databases Searched 
 
 
 
Tabl 
e Vendor/ 
Interface 
 
Database Date 
searched 
Database 
update 
 
Searcher(s) 
 
1a 
National 
Library of 
Medicine 
Multiple 
Database 
 
6/17/2017 
 
6/17/2017 50778587 ZHOU 
TOLYBERT 
 
1b 
EBSCOho 
st 
Research 
Databases 
Multiple 
Database 
 
6/24/2017 
 
6/24/2017 
 
50778587 ZHOU 
TOLYBERT 
1c Ovid Multiple Database 6/24/2017 6/23/2017 
50778587 ZHOU 
TOLYBERT 
1d Informit multiple databases 7/3/2017 7/3/2017 
50778587 ZHOU 
TOLYBERT 
1e Proquest multiple databases 7/3/2017 7/3/2017 
50778587 ZHOU 
TOLYBERT 
1f WEB OF SCIENCE 
multiple 
databases 7/3/2017 7/3/2017 
50778587 ZHOU 
TOLYBERT 
     
     
 
 
 
Table 1a National Library of Medicine search strategy 
Provider/Interface National Library of Medicine 
Database    PubMed 
Date searched June 17, 2017 
Database update   June 17, 2017 
Search developer(s)  50778587 ZHOU TOLYBERT 
Limit to English    Yes 
Date Range Publication date from 1996/01/01 
 
 
Search (((HIV-1*) OR human immunodeficiency virus*)))) AND ((((HIV Viral  
Load Monitoring Frequency[Title/Abstract]) OR frequency of plasma HIV-1  
RNA monitoring[Title/Abstract]) OR rates of HIV-1 viral load  
monitoring[Title/Abstract]) OR Frequency of HIV-1 viral load  
monitoring[Title/Abstract]) OR human immunodeficiency virus RNA  
measurement[Title/Abstract]) OR frequent routine monitoring[Title/Abstract])  
OR Frequency Virological monitoring[Title/Abstract]))) Filters: Publication date 
#1 from 1996/01/01 
 
 
 
 
Table 1b: EBSCOhost Research Databases 
 
 
Provider/Interface 
Database 
Date searched  
Database update 
Search 
developer(s)  
Limit to English 
Date Range 
 
Provider/Interface 
 
 
EBSCOhost Research 
Databases 
Multiple Databases 
6/24/2017 
6/24/2017 
50778587 ZHOU TOLYBERT 
Yes 
Publication date from 
1996/01/01 
EBSCOhost Research 
Databases 
 
 
 
 
 
 
S1 
TX HIV Viral Load Monitoring Frequency OR TX frequency of plasma HIV-1 
RNA monitoring OR TX rates of HIV-1 viral load monitoring OR TX Frequency 
of HIV-1 viral load monitoring OR TX human immunodeficiency virus RNA 
measurement OR TX frequent routine monitoring OR TX Frequency Virological 
monitoring 
 Limiters - Publication Date: 19960101-20171231; Hidden NetLibrary Holdings 
 Narrow by Subject: - diagnosis 
 Narrow by Subject: - viremia 
 Narrow by Subject: - viraemia 
 Narrow by Subject: - plasma (blood) 
 Narrow by Subject: - blood plasma 
 Narrow by Subject: - aids 
 Narrow by Subject: - acquired immune deficiency syndrome 
 Narrow by Subject: - human immunodeficiency virus 
 Narrow by Subject: - antiretroviral agents 
 Narrow by Subject: - drug therapy 
 Narrow by Subject: - human immunodeficiency virus type 1 
 Narrow by Subject: - rna 
 Narrow by Subject: - hiv-1 infections 
 
 
 
 
 
 Narrow by Subject: - antiviral agents 
 Narrow by Subject: - human immunodeficiency virus infections 
 Narrow by Subject: - hiv infections 
 Narrow by Subject: - viral load 
 Narrow by Subject: - human immunodeficiency virus 1 
 Narrow by SubjectMajor: - drug resistance 
 Narrow by SubjectMajor: - treatment failure 
 Narrow by SubjectMajor: - monitoring 
 Narrow by SubjectMajor: - diagnosis 
 Narrow by SubjectMajor: - viraemia 
 Narrow by SubjectMajor: - regimens 
 Narrow by SubjectMajor: - blood plasma 
 Narrow by SubjectMajor: - acquired immune deficiency syndrome 
 Narrow by SubjectMajor: - antiretroviral agents 
 Narrow by SubjectMajor: - drug therapy 
 Narrow by SubjectMajor: - rna 
 Narrow by SubjectMajor: - hiv-1 infections 
 Narrow by SubjectMajor: - antiviral agents 
 Narrow by SubjectMajor: - hiv infections 
 Narrow by SubjectMajor: - human immunodeficiency viruses 
 Narrow by SubjectMajor: - viral load 
 Narrow by SubjectMajor: - human immunodeficiency virus 1 
 Narrow by SubjectThesaurus: - azt (drug) 
 Narrow by SubjectThesaurus: - viremia 
 Narrow by SubjectThesaurus: - diagnosis 
 Narrow by SubjectThesaurus: - virology 
 Narrow by SubjectThesaurus: - blood plasma 
 
 
 
 
 
 Narrow by SubjectThesaurus: - aids (disease) 
 Narrow by SubjectThesaurus: - drug therapy 
 Narrow by SubjectThesaurus: - highly active antiretroviral therapy 
 Narrow by SubjectThesaurus: - hiv (viruses) 
 Narrow by SubjectThesaurus: - hiv-positive persons 
 Narrow by SubjectThesaurus: - viral load 
 Narrow by SubjectThesaurus: - rna 
 Narrow by SubjectThesaurus: - antiviral agents 
 Narrow by SubjectThesaurus: - antiretroviral agents 
 
 
 
Table 1c: Ovid search strategy 
 
 
Provider/Interface  Ovid 
Database Multiple Database 
Date searched 6/24/2017 
Database update 6/24/2017 
Search 50778587 ZHOU TOLYBERT 
developer(s) 
Limit to English Yes 
Date Range Publication date from 
1996/01/01 
Provider/Interface  Ovid 
 
 
#1 (HIV-1 or human immunodeficiency virus).af. 
 
 
 
#2 
(HIV Viral Load Monitoring Frequency or frequency of plasma HIV-1 RNA 
monitoring or rates of HIV-1 viral load monitoring or human immunodeficiency 
virus RNA measurement Frequency of HIV-1 viral load monitoring or frequent 
routine monitoring or Frequency Virological monitoring).af. 
#3 1 AND 2 
     
     
 
 
 
Table 1d: Informit search strategy 
 
 
Provider/Interface  informit 
Database multiple databases 
Date searched 7/3/2017 
Database update 7/3/2017 
Search 50778587 ZHOU TOLYBERT 
developer(s) 
Limit to English Yes 
Date Range Publication date from 
1996/01/01 
Provider/Interface  informit 
 
(ALLTERMS,FC:frequency ALLTERMS,FC:of ALLTERMS,FC:plasma 
ALLTERMS,FC:HIV-1 ALLTERMS,FC:RNA ALLTERMS,FC:monitoring) OR 
(ALLTERMS,FC:HIV ALLTERMS,FC:Viral ALLTERMS,FC:Load  
ALLTERMS,FC:Monitoring ALLTERMS,FC:Frequency) OR  
(ALLTERMS,FC:rates ALLTERMS,FC:of ALLTERMS,FC:HIV-1  
ALLTERMS,FC:viral ALLTERMS,FC:load ALLTERMS,FC:monitoring) AND 
(ALLTERMS,FC:HIV-1 OR ALLTERMS,FC:human 
#1  ALLTERMS,FC:immunodeficiency ALLTERMS,FC:virus) 
 
     
     
 
 
 
 
 
Table 1e: Proquest search strategy 
 
 
Provider/Interface  Proquest 
Database multiple databases 
Date searched 7/3/2017 
Database update 7/3/2017 
Search 50778587 ZHOU TOLYBERT 
developer(s) 
Limit to English Yes 
Date Range Publication date from 
1996/01/01 
Provider/Interface  Proquest 
 
ab(HIV Viral Load Monitoring Frequency) OR ab(frequency of plasma HIV-1 
RNA monitoring) OR ab(rates of HIV-1 viral load monitoring) OR ab(Frequency 
of HIV-1 viral load monitoring) OR ab(human immunodeficiency virus RNA 
measurement) OR ab(frequent routine monitoring) OR ab(Frequency 
#1 Virological monitoring) 
 
 
 
 
 
 
Table 1f: WEB OF SCIENCE search strategy 
 
 
Provider/Interface  WEB OF SCIENCE 
Database multiple databases 
Date searched 7/3/2017 
Database update 7/3/2017 
Search 50778587 ZHOU TOLYBERT 
developer(s) 
Limit to English Yes 
Date Range Publication date from 
1996/01/01 
Provider/Interface  WEB OF SCIENCE 
 
 
 TITLE: (frequency of plasma HIV-1 RNA monitoring) OR TITLE: (Frequency of 
Virological monitoring) OR TITLE: (frequent routine 
monitoring) ORTITLE: (human immunodeficiency virus RNA 
measurement) OR TITLE: (Frequency of HIV-1 viral load 
monitoring) OR TITLE: (rates of HIV-1 viral load monitoring) OR TITLE: (HIV 
Viral Load Monitoring Frequency) ANDTOPIC: (HIV-1) 
 Timespan: 1996-2017. 
 Search language=Auto 
 
 
 
 
   
   
      
      
 
 
 
 
 
 
 
 
      
    
 
 
 
 
 
Table 1g: Other sources search strategy table 
 
 
 
 
Data Source 
 
Results 
Vendor/ Interface Database New 
Author Search n/a 0 
bibliographies bibliographies 4 
Handsearching 
and/or 
Conferences 
handsearching journals 
& conference 
proceedings 
 
0 
Google Google Scholar 0 
Total 4 
 
 
 
Bibliographies searched 
 
 
 
CANIGLIA, E.C.S.D., SABIN, C., ROBINS, J.M., LOGAN, R., CAIN, L.E., ABGRALL, S., 
MUGAVERO, M.J., HERNANDEZDIAZ, S.D.H., MEYER, L., SENG, R., DROZD, D.R., SEAGE, 
G.R.I.I.I., BONNET, F., DABIS, F., MOORE, R.R., REISS, P., VAN SIGHEM, A., MATHEWS, W.C.,  
DEL AMO, J., MORENO, S., DEEKS, S.G., MUGA, R., BOSWELL, S.L., FERRER, E., ERON, J.J.,  
NAPRAVNIK, S., JOSE, S., PHILLIPS, A., OLSON, A., JUSTICE, A.C., TATE, J.P., BUCHER, H.C.,  
EGGER, M., TOULOUMI, G., STERNE, J.A., COSTAGLIOLA, D., SAAG, M., HERNAN, M.A.D.H.  
and ON BEHALF OF THE CENTER FOR AIDS RESEARCH NETWORK OF INTEGRATED  
CLINICAL SYSTEMS AND THE HIVCAUSAL COLLABORATION, 2016. When to Monitor CD4 Cell  
Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV- 
Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational  
Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 72(2), pp. 214-221. 
ROMIH, V., ZIDOVEC LEPEJ, S., GEDIKE, K., LUKAS, D. and BEGOVAC, J., 2010. Frequency of 
HIV-1 viral load monitoring of patients initially successfully treated with combination antiretroviral 
therapy. PloS one, 5(11), pp. e15051. 
 
